



Titre: Unravelling the complexities of depression with medical intelligence: exploring the interplay of genetics, hormones, and brain function
Title:

Auteurs: Md Belal Bin Heyat, Faijan Akhtar, Farwa Munir, Arshiya Sultana, Abdullah Y. Muaad, Ijaz Gul, Mohamad Sawan, Waseem Asghar, Sheikh Muhammad Zeeshan Iqbal, Atif Amin Baig, Isabel de la Torre Díez, & Kaishun Wu
Authors:

Date: 2024

Type: Article de revue / Article

Référence: Belal Bin Heyat, M., Akhtar, F., Munir, F., Sultana, A., Y. Muaad, A., Gul, I., Sawan, M., Asghar, W., Muhammad Zeeshan Iqbal, S., Amin Baig, A., de la Torre Díez, I., & Wu, K. (2024). Unravelling the complexities of depression with medical intelligence: exploring the interplay of genetics, hormones, and brain function. *Complex & Intelligent Systems*, 10(4), 5883-5915.
Citation: <https://doi.org/10.1007/s40747-024-01346-x>

Document en libre accès dans PolyPublie

Open Access document in PolyPublie

URL de PolyPublie: <https://publications.polymtl.ca/65400/>
PolyPublie URL:

Version: Version officielle de l'éditeur / Published version
Révisé par les pairs / Refereed

Conditions d'utilisation: Creative Commons Attribution 4.0 International (CC BY)
Terms of Use:

Document publié chez l'éditeur officiel

Document issued by the official publisher

Titre de la revue: Complex & Intelligent Systems (vol. 10, no. 4)
Journal Title:

Maison d'édition: Springer
Publisher:

URL officiel: <https://doi.org/10.1007/s40747-024-01346-x>
Official URL:

Mention légale: This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
Legal notice:



permission directly from the copyright holder. To view a copy of this licence, visit
<http://creativecommons.org/licenses/by/4.0/>.



Unravelling the complexities of depression with medical intelligence: exploring the interplay of genetics, hormones, and brain function

Md Belal Bin Heyat^{1,2} · Faijan Akhtar³ · Farwa Munir⁴ · Arshiya Sultana⁵ · Abdullah Y. Muaad⁶ · Ijaz Gul^{7,8} · Mohamad Sawan² · Waseem Asghar^{9,10} · Sheikh Muhammad Asher Iqbal^{9,10} · Atif Amin Baig¹¹ · Isabel de la Torre Díez¹² · Kaishun Wu^{1,13}

Received: 26 April 2023 / Accepted: 23 December 2023 / Published online: 4 April 2024
© The Author(s) 2024

Abstract

Depression is a multifactorial disease with unknown etiology affecting globally. It's the second most significant reason for infirmity in 2020, affecting about 50 million people worldwide, with 80% living in developing nations. Recently, a surge in depression research has been witnessed, resulting in a multitude of emerging techniques developed for prediction, evaluation, detection, classification, localization, and treatment. The main purpose of this study is to determine the volume of depression research conducted on different aspects such as genetics, proteins, hormones, oxidative stress, inflammation, mitochondrial dysfunction, and associations with other mental disorders like anxiety and stress using traditional and medical intelligence (medical with AI). In addition, it also designs a comprehensive survey on detection, treatment planning, and genetic predisposition, along with future recommendations. This work is designed through different methods, including a systematic mapping process, literature review, and network visualization. In addition, we also used *VOSviewer* software and some authentic databases such as Google Scholar, Scopus, PubMed, and Web of Science for data collection, analysis, and designing comprehensive picture of the study. We analyzed 60 articles related to medical intelligence, including 47 from machine learning with 513,767 subjects (mean \pm SD = 10,931.212 \pm 35,624.372) and 13 from deep learning with 37,917 subjects (mean \pm SD = 3159.75 \pm 6285.57). Additionally, we also found that stressors impact the brain's cognitive and autonomic functioning, resulting in increased production of catecholamine, decreased cholinergic and glucocorticoid activity, with increased cortisol. These factors lead to chronic inflammation and hinder the brain's normal functioning, leading to depression, anxiety, and cardiovascular disorders. In the brain, reactive oxygen species (ROS) production is increased by IL-6 stimulation and mitochondrial cytochrome c oxidase is inhibited by nitric oxide, a potent inhibitor. Proteins, lipids, oxidative phosphorylation enzymes, and mtDNA are further disposed to oxidative impairment in the mitochondria. Consequently, mitochondrial dysfunction exacerbates oxidative stress, impairs mitochondrial DNA (mtDNA) or deletions of mtDNA, increases intracellular Ca^{2+} levels, changes in fission/fusion and mitochondrial morphology, and lastly leads to neuronal death. This study highlights the multidisciplinary approaches to depression with different aspects using traditional and medical intelligence. It will open a new way for depression research through new emerging technologies.

Keywords Brain · Cardiac · Molecule · Detection · Inflammation · Mitochondrial dysfunction · Artificial intelligence · Therapy · Prediction · Oxidative stress · Medicine · Unani medicine · Herbal medicine

Introduction

In recent days, human lifestyle has changed due to pandemic scenarios affected by psychological and neurological behavioral changes that has led to depression and anxiety [1, 2]. As per WHO, depression is anticipated to be the second most significant reason for infirmity in 2020 affecting about

50 million people worldwide, with 80% living in developing nations [3]. Human psychological disorders like anxiety disorder, mood disorder, and depression are associated with human behavior and are also connected with eating disorders [4]. The negative effects of depression on the human brain have been linked to the increased neuro-pathologies caused by prevalent neurodegenerative illnesses including Alzheimer's, Parkinson's, and Huntington's [5, 6]. Neurological disorders like epilepsy, migraine, stroke and multiple

Extended author information available on the last page of the article

sclerosis decrease the quality of health. Also, it has been seen that anxiety and depression impact low health and quality of life [7]. Stress leads to depression and tension, affecting the physiology of neuro-immune consequences, and it has been observed that focus is more effective in women than men [8].

Mental health has a very essential role in personal well-being and public health. According to WHO, mental health illness is categorized as a global public health problem [9, 10]. Depression is categorized as a severe medical illness for personal and general mental health, and depression can be seen regardless of age, gender, and financial status [11–13]. Depression could be a factor affecting negative impact on the lifestyle of an individual leading to social life disruptions [14]. In addition, clinical depression can be addressed by symptoms like feelings of sadness, loss of appetite, sleep cycle disturbances, guilt, incapable of decision making, which could result in self-harm attempts [15]. There are three categories of depression stages. Depression among various populations is associated with physical illness, severe neuropsychological impairment, and low clinical outcomes [14]. Depression is considered a neurological disorder that affects worldwide 3 million people yearly [11].

While significant effort has been made to investigate the pathophysiology and molecular causes of the disease using a variety of methods, the exact cause of Depression is still unknown. From a physiological perspective, Depression is characterized by symptom heterogeneity and alterations in numerous bodily systems. In general, a number of factors, including genetic, environmental, and psychological ones, work together to cause Depression. Depression is a complex health problem, it cannot be tailored by focusing only on one aspect [16]. There exist various diagnostic methods for depression, and they are time-consuming. Also, most of them followed self-reporting or self-diagnosis of patients [12], and are well known to be consulting a psychiatrist or psychologist [11, 13]. In other words, there have been several well-established techniques available for diagnosis, and require experienced health professionals. There is a possibility of misdiagnosis due to overlapping symptoms of the different disorders. Hence, this situation could lead to an increased risk of prolonged major depression. Diagnosis is an essential aspect of depressive disorder treatment in time and is responsible for recovery.

Previous research has mostly looked into particular medical diseases linked to depression because of the complexity and variability of medical data. It has been proved that the use of "big data" and machine-learning techniques and algorithms can uncover important patterns and connections in health data while handling heterogeneous data without rigid limits [17]. In the diagnosis of the associated factors of depression, artificial intelligence (AI) can help at greater extent. New techniques of machine learning and deep learning have made diagnosis and treatment better [18, 19].

Recent research on reaction–diffusion terms in genetic regulatory networks has produced numerous impressive findings, including stability, state estimation, and sampled-data state estimation. One of the most popular topics and ones with promising outcomes is the study of reaction–diffusion neural networks (RDNNs), such as the dynamical analysis of impulsive RDNNs (IRDNNs). The stability is hardly ever obtained when the neural networks are impacted by external input. Therefore, the Sontag-originally conceived input-to-state stability (ISS) is used to assess how external input affects the stability of neural networks [20]. Based on these newly emerging techniques it can be assumed that such techniques can help in diagnosing the underlying issue of depression too. A person's brain structure may change as a result of depression, which can also have psychological effects. Repeated stressful events can eventually harm the human brain in long-term depression. Human brain structural changes can include cortical atrophy, oxygen deprivation, and inflammation. So these complex changes in the near future can be diagnosed and treated by RDNNs, ISS and non-linear dynamics [21].

We have accumulated recent research to address depression and its associates. We have conducted this review to handle important information related to depression-like effects, detection, treatment, and psycho-neurological human behaviors such as stress and anxiety. Previously, there is not a reliable review or meta-analysis available as comprehensive as this one, to the best of our knowledge. This review aims to outline and analyze numerous issues associated with depression among humans and deliver an explanation to the following research questions (RQs):

RQ1: What is the relationship between depression, stress, and anxiety?

RQ2: What are the effects of depression on the human brain and cardiac systems in relation to oxidative stress, inflammation, and mitochondrial dysfunction in depression?

RQ3: What are the effects of depression on genes, proteins, and hormones in the human body?

RQ4: What is the major role of medical intelligence in depression?

RQ5: What is the concept for treating and diagnosing depression patients?

Additionally, the main contribution of this survey is given below:

- To find out the association of psycho-neurological human behavior such as stress and anxiety with depression.
- To find out the changes in genes, proteins, hormones, oxidative stress, inflammation, mitochondrial dysfunction, brain, and cardiac during depression.
- To find the major role of medical intelligence (medical + artificial intelligence) in the detection, prediction, classification, recommendation, and treatment of depression.

Table 1 Criteria of this study

Criteria	Inclusion	Exclusion	Justification
Subject	Studies that emphasize only depression with the brain, cardiac, gene, protein, hormone, machine learning, deep learning, detection, treatment, stress, and anxiety	Studies that dealt with depression with other diseases except for stress and anxiety	Studies that involved other diseases would not answer our research questions
Language	English	Other languages like Chinese, Spanish, Japanese, and Koreans	Chances of misinterpretation as the data in other languages may thus affect the accurateness
Access	Full text	Nonavailability of full-text	To ensure the interpretation is more accurate
Method	All	No exclusions	For a complete view
Type of article	Research, review articles, conference proceeding	Book, chapter, news, editorial, and encyclopedia	Excluded articles containing broad widespread discussion over a theme may not adequately response our specific research questions

Table 2 Search strategies of this study are based on RQs

RQ no	Keywords
1	Depression, stress, anxiety
2	Depression, brain, heart, oxidative stress, mitochondria, inflammation, dysfunction
3	Depression, gene, protein, hormone
4	Depression, machine learning, deep learning, artificial intelligence
5	Depression, treatment, diagnosis, unani medicine, allopathic, modern medicine

- To find the treatment and diagnosis based on the present scenario with research gap and future recommendations for upcoming researchers, doctors, scientists, and scholars.
- To design and suggest the closest terms based on previous and current studies using *VOSviewer* and word clouds to help readers, students, researchers, doctors, scientists, and academicians.

The rest of this survey discusses the methodology of the review, followed by answering the research questions (relationship, effect, role, detection, and treatment), along with the discussion (importance of the present study, network visualization, world cloud, and comparisons), research gaps of the previous studies, and future directions or ideas about work on depression in different aspects like medically, biologically, psychologically, and engineering.

Methods

The following steps were performed in the methods: (a) planning as per PRISMA checklist for publication (b) accomplished a comprehensive literature exploration for information (c) data extraction (d) data analyses (e) analysis of subgroups or subsets, and (f) reporting results [22, 23].

Eligibility criteria

The article selection procedure was divided into two stages. The initial step included one of the authors to assess publications based on the title and abstract. Four scholars independently analyzed publications that were screened. After carefully reviewing the data, the four authors extracted the data independently to prevent bias, and the results were structured in a table. Table 1 listed numerous factors considered while determining exclusion and inclusion criteria.


Information source and search strategies

We compiled relevant literature linked to depression available on Google Scholar, Scopus, PubMed and Web of Science databases using an automated search. These databases are most popular in the modern and traditional research in the world. We widened our search terms and categories to gather enough research relating to our topics. Table 2 lists the keywords utilized in the literature search based on RQs.

Data selection and collections

We looked at papers' titles, keywords, and abstracts to define their aptness and relevance for inclusion in this review. Data

Fig. 1 Application of AI in the depression



from primary studies was effectively extracted, and the quality of the data was independently reviewed. The final decision on inclusion were made, and articles were selected from 1996 to 2023. Four researchers independently analyzed and extracted the data. For any disagreement, the data for the confirmation was reviewed by three other researchers. The PRISMA checklist was referred for the assessment [24]. This paper include detailed records regarding the major role of medical intelligence in depression details of previously published work using machine learning and deep learning in depression were evaluated through objective, the number of subjects, dataset, domains, classifier, and performance measures were documented. Any disagreements among the writers were settled by consensus. In addition, the relation between depression, stress, and anxiety, the effects and relation of depression on brain and cardiac systems with the relation between oxidative stress, inflammation, and mitochondrial dysfunction in depression, the effect of depression on gene, protein, and hormone, and treatment and diagnosis of depression patients with evidence-based studies with the mechanism of action of natural bioactive molecules in medicinal plants for depression.

Synthesis of the result

Statistical methods were performed for the strategy of data synthesis. The major role of medical intelligence in the depression details of previously published work using machine learning and deep learning in depression were evaluated through objectives, the number of subjects, dataset, domains, classifier, and performance measures. We also

retrieved related to depression with machine learning and deep learning such as per (a) publication under open access and subscription, (b) year-wise publications, and (c) country-wise share, in the Web of Science database. Additionally, we designed a Network visualization based on a previously published article related to this study.

Medical intelligence in the depression

Medical Intelligence terms are made up of medical and artificial intelligence (AI). The application of artificial intelligence is summarized in Fig. 1. Machine learning is growing as a dynamic research area in many fields of science including computer vision, natural language processing, speech recognition, genes expression, image recognition, and signal processing, [25–27]. Whereas deep learning is a subset of the machine learning that learns the learning process. Deep neural network is a branch of deep learning and can be employed in extracting information from signals.

Filho et al. [28] assessed the effectiveness of machine learning algorithms in identifying patients with depression by analyzing clinical, laboratory, and sociodemographic data collected from the Brazilian National Network for Research on Cardiovascular Diseases between June 2016 and July 2018. Zhang et al. [29] developed a machine-learning framework to predict the risk of postpartum depression (PPD) using data extracted from electronic health records (EHRs). Poletti et al. [30] emphasized the importance of innovative tools for early diagnosis of bipolar disorder (BD), the integration of biomarker research into clinical practice, and the

development of novel therapeutic strategies for depressive disorders. Pearson et al. [31] found that multiple variables can predict symptom improvement following an Internet intervention, although each variable contributes only modestly. Hochman et al. [32] created and validated a machine learning-based model for predicting PPD using electronic health record (EHR) data, and discovered new predictors for PPD. Liu et al. [33] aimed to enhance the response to reward-related stimuli in major depressive disorder (MDD) by targeting dopaminergic signaling in the entire brain. Kambeltz et al. [34] developed an algorithm that utilizes clinical patterns and machine learning to predict the response of transcranial direct current stimulation (tDCS) and escitalopram in individuals with major depression. Na et al. [35] focused on constructing a predictive model based on machine learning to anticipate the future onset of depression. Helbich et al. [36] studied 1190 people aged 60 and up in a cross-sectional study. The abbreviated Geriatric Depression Scale assessed depressive symptoms (GDS-15). A fully convolutional neural network extracted streetscape green and blue spaces from Tencent Street View data. On a neighborhood level, indicators produced from street view photos were compared to those derived from satellite-based normalized difference water index (NDWI), normalized difference vegetation index (NDVI), and GlobeLand30 land cover data. Multilevel regressions with neighborhood-level random effects were used to determine the relationships between neighborhood-levels green and blue regions. They concluded that green and blue areas in the street view are protective against depression in the elderly in China, but longitudinal confirmation is needed to infer causality. Different characteristics of natural habitats are represented by the street view and satellite-derived green and blue space metrics. Street view data and deep learning are useful tools for automated environmental exposure assessments. Oh et al. [37] reported that a deep-learning approach had got AUC of 0.91 and 0.89 for predicting depression in NHANES and K-NHANES, respectively. With an AUC of 0.92, a deep-learning algorithm trained on serial datasets predicted the prevalence of depression in the next two years of data. NHANES with machine learning classifiers could help predict depression in K-NHANES. The maximum performance (AUC: 0.77) was achieved using logistic regression, followed by the deep learning method (AUC: 0.74). Mumtaz et al. [38] could change clinical applications for EEG-based depression detection. Based on the findings, it is possible to conclude that the deep learning framework might be used to diagnose depression automatically. Gui et al. [39] have used a convolutional neural network (CNN) with local residual response to represent four different types of functional magnetic resonance imaging (fMRI) data obtained by depressed patients and healthy persons while listening to happy and negative

emotions music. To match the features and obtain the correlation matrix, they utilized a large convolution kernel of the same size as the correlation matrix. At the beginning four-dimensional fMRI data was utilized to create a two-dimensional correlation matrix of one person's brain based on ROIs, which was then processed using a threshold value chosen based on complex network and small-world network properties. In this article, the deep learning model is compared for classification with other algorithms. Finally, researchers compute matching ROIs from the intermediate outputs of their deep learning model, which can aid in further research in related disciplines. Furthermore, in [40], mainly focused on visual and auditory markers of patients functioning for clinical diagnosis, therapy selection, and prognosis, detection method. Identifying these signals helped improve clinical assessment consistency, sensitivity, and scalability. They wanted to see if clinical features from free speech responses to a brief interview, one month after trauma, could be captured using machine learning-based semantic, computer vision, and acoustic analysis to classify MDD and PTSD. Concluding, audio visual markers can be helpful tools to measure post trauma status of patients with MDD and PTSD. In another study by Little et al. [14] twenty-nine patients with Late-life depression (LLD) and 29 age-matched controls wore a wrist-worn device that captured their acoustic surroundings for seven days. Deep learning models were constructed and verified on an independent speech dataset to automatically interpret acoustic input. While respecting participants' privacy, total speech activity and the proportion of speech produced by the device wearer were recognized. A neuropsychological test battery, as well as clinical and self-report scales along with general and social functioning were used to assess the degree of depression. Using graph theory, Li et al. [13] investigated aberrant structure in the functional connectivity network of moderate depression in [7]. Second, they suggested a new categorization model for mild depression recognition. Third, they used CNN to process two-dimensional reparatory from the 2D data form the functional connectivity matrices using EEG. Inspired by recent breakthroughs in the ability of deep recurrent CNNs, to classify mental load. The classification model correctly identified mild depression with an accuracy of 80.74% [11]. According to the findings, combining a CNN with a functional connectivity matrix could give a potential objective method for detecting moderate depression. Numerous studies based on machine learning and deep learning employing electroencephalogram (EEG) have been undertaken [11]. The asymmetry matrix picture achieved 98.85% accuracy in the alpha band, outperforming most of the methods given in earlier studies [11]. To detect depression, Knag et al. [11] developed a deep model based on CNN and long short-term memory (LSTM). The local features and EEG signal

sequence are learned using CNN and LSTM. To build feature maps in the deep learning model, filters convolve with the input signal in the convolution layer. All the collected characteristics are fed into the LSTM, which learns various patterns in the signal before doing classification using fully connected layers. The memory cells in the LSTM allow it to recall important features for a long time. It also includes several functions for updating the weights during workouts. The model was tested using a random splitting technique, which yielded an accuracy of 99.07% and 98.84% for the right and left hemisphere EEG signals, respectively. Zhang et al. [41] concluded a clinical trial on the handling of epileptic patients with anxiety and sadness using electronic nerve stimulation from the Internet of things. They start their paper by employing literary technique to investigate the origins of epilepsy and previous treatment methods. Finally, the assessment of epileptic symptoms, sadness, and anxiety before and after therapy between the observation and the control groups were examined. They discovered that, of the 50 cases in the trial, the observation group that employed electrical nerve stimulation therapy had five people who stopped having seizures following treatment, accounting for 10%, whereas the control group using traditional medicine had none. Furthermore, the observation group's SAS and SDS ratings were minor than those of the control group. As a result, using electrical nerve stimulation, to treat epilepsy with anxiety and depression, has improved presentation and can assist patients in speedy recovery. In addition, the most common performance measures of the machine learning model are used in the depression are mentioned in Eqs. (1)–(4) [42–50] below:

$$\text{Accuracy} = \frac{\text{True positive} + \text{True negative}}{\text{False positive} + \text{False negative} + \text{True negative} + \text{True positive}} \quad (1)$$

$$\text{Specificity} = \frac{\text{True negative}}{\text{True negative} + \text{False positive}} \quad (2)$$

$$\text{Sensitivity} = \frac{\text{True Positive}}{\text{True positive} + \text{False negative}} \quad (3)$$

$$\text{Precision} = \frac{\text{True positive}}{\text{True positive} + \text{False positive}} \quad (4)$$

We have designed the database related to the role of the machine and deep learning in depression based on previous studies, mentioned in Fig. 2. It is evaluated based on open access (59%) and subscription (41%) publications, year-wise and country-wise. In the country-wise publications, the United States of America (USA) has the highest (16%), China (14%), and India (12%) is in second and third numbers, respectively. We found that related to machine and deep learning in depression 59% papers are published as open access and 41% of papers published as subscription or close access. In year-wise publication highest rate is in

2019 and 2021 (31%) and the lowest rate is in 2018 and 2022 (3%). While, in country wise publication, USA (16%), China (14%), and India (12%) is in Top 3 and in lowest Argentina (2%), Australia (2%), Canada (2%), Germany (2%), Norway (2%), Spain (2%), Thailand (2%), Turkey (2%), Italy (2%), Japan (2%), Malaysia (2%), and New Zealand (2%). These details would be helpful for researchers, doctors, and scholars to work in this area. In addition, we have also evaluated the previously published research article related to depression with machine learning and deep learning shown in Tables 3 and 4.

Association between depression, stress, and anxiety

Three important terms define psychological distress: stress, anxiety, and depression. Stress is a mental or physical sign such as irritability or digestive trouble whereas anxiety is defined as transient fear and uncertainty about the future. Its severity depends on the intensity and frequency of experiencing anxiety [93]. Stress is caused by several foreign stimuli, such as the daily stressful events, school grades of adolescents, and financial problems of adults, which can result in irritability. Prolonged irritability and helplessness to solve problems cause chronic stress, leading to depressive disorders [94]. Anxiety disorders include general and perinatal anxiety, phobia, panic syndromes, social anxiety syndrome, obsessive–compulsive disorder (OCD), post-traumatic stress disorder, and body dysmorphic syndrome [95]. Chronic stress and anxiety can result in depression [96]. There is evidence for the accumulating effect of daily stressors on cardiac health, such as unhealthy eating practices and a sedentary lifestyle [97]. Daily stressors impact human health which leads to worry, and these prolonged everlasting worries lead to a depressive state. Major depressive disorder affects the quality of life (QoL). Numerous studies have established and explored the relation between depression and QoL [98]. Psychological stress is a significant factor in major depressive disorders in animal and human models. Chronic psychological stress activates inflammatory pathways resulting in inflammation [99]. Resultant inflammation leads to Cardiac heart diseases (CHD) and neurological deformities. Stressors impact the brain's cognitive and autonomic functioning, resulting in the increased production of catecholamine, decreased cholinergic activity, decreased glucocorticoid activity, and increased cortisol. These factors lead to chronic inflammation and hinder brain's normal working, leading to depression, anxiety, and cardiovascular disorders [100]. In major depressive disorders, neurotransmitters such as catecholamine, norepinephrine, and/or dopamine have important roles [101]. However, the role of the catecholamine




Fig. 2 Details for the previously published articles related to depression with machine learning and deep learning such as **a** publication under open access and subscription, **b** year-wise publications, and **c** country-wise share, in the Web of Science database

actions in the pathophysiology of major depression is understood partially. Norepinephrine binds to α 1- and β -adrenergic receptors and results in a stimulatory influence on cell signaling; specifically, increases intracellular phospholipase C and cAMP. However, stimulation of the α 2-adrenergic receptor subdues intracellular cAMP and inhibits signaling [102]. In melancholic depression, norepinephrine stimulates anxiety and hyperarousal, promotes corticotropin-releasing hormone-mediated hypercortisolism, promotes insulin resistance, and causes bone loss [103]. In an experimental investigation, the urinary catecholamine was measured in depressed and everyday individuals. Catecholamine levels were found to be significantly increased in depressed individuals [104]. Terms such as stress, anxiety and depression are frequently used where the stress is a basic short-term

issue which if left untreated can lead to anxiety. Anxiety is a chronic issue that can become the cause of major depressive disorder. In this vicious cycle sometimes depression results in anxiety too. The relation between stress, depression and anxiety is illustrated in Fig. 3.

Depression and anxiety increase plasma catecholamine that results in the reactive oxygen species (ROS) formation. ROS formed in a depressed state can further affect the coding and non-coding regions. ROS causes transient dynamics of si-IncrRNA in the nucleus. It accumulates in polysome, replacing mRNA and causing transcriptional stress [105]. The impact of stress on the molecular level can be different in both genders. An experimental study concluded that the Dusp6 gene is downregulated in stress affecting the transcriptional pathway in female mice, whereas ERK signaling

Table 3 Previously published work using machine learning in depression evaluated through objective, the number of subjects, dataset, domains, classifier, and performance measures

Reference	Objective	Subj	Dataset	Domain	Classifier	Performance measures
[30]	Discrimination	240	MDD, BD, HC	Mood disorder	Bootstrap	Accuracy: 97.00%
[29]	Prediction	69,169	HER, WCM, CDRN	Pregnant women	RF, DT, XGB, LR, MLP	AUC: 0.937 (95% CI 0.912–0.962) and 0.886 (95% CI 0.879–0.893)
[28]	Evaluation	971	Brazilian National Network for Research on Cardiovascular Diseases	–	LR, KNN, CART, AB, GB, XGB, RF, SVM	accuracy: 89.00%, sensitivity: 90.00%, AUC: 0.87
[32]	Development and validation	214,359	CHS-EHR	PPD	DT	AUC: 0.712 (95% CI 0.690–0.733), sensitivity: 34.90%, specificity: 90.50%
[51]	Prediction	167	CHR syndromes and ROD	Psychosis	–	Accuracy: 85.50%, sensitivity: 84.6%; specificity: 66.8%; $P < 0.001$
[52]	Development	335	60 years or older with Parkinson's disease	–	SVM	accuracy: 95.00%
[53]	Differentiation	126	Hebrew speakers with normal or corrected-to-normal eyesight	–	Bagged DT	Accuracy: 74.18%
[54]	Cross-trial prediction	351	STEPd	Psychotherapy	–	–
[55]	Prediction	28,755	Pregnancy Risk Assessment Monitoring System 2012 to 2013	PPD	RF	Accuracy: 79.10%
[56]	Classification	79 889	English-speaking health forums	–	NLP	–
[57]	Classification and prediction	150	Mohammed VI University Hospital Center of Marrakech	–	RF	Accuracy: 99.00%
[58]	Analysis	168	MDD case-control	Blood microRNA	GBM	AUC: 0.97
[59]	Detection	–	Twitter	–	SVM, NB, DT	–
[60]	Prediction	221	12 weeks problem-solving or supportive therapy	Psychotherapies for late-life depression	RF	Accuracy: 80.00%
[61]	Prediction	–	IMID	–	LR, NN, RF	AUC: 0.91
[62]	Prediction	518	iSPOT-D	Antidepressant treatment	GBT	–
[63]	Identification	365	Reddit posts from fathers, straddling six months during the birth of the kid	Fathers at risk of PPD	SVM	Sensitivity: 82.00%

Table 3 (continued)

Reference	Objective	Subj	Dataset	Domain	Classifier	Performance measures
[64]	Recognition	9435	Population-representative sample	Physical and social neighborhood characteristics	GLM, GBM	SD: 4.913
[65]	Diagnosis	412	Amazon Mechanical Turk	Mobile usage attributes	RF	Accuracy: 76.80%
[66]	Prediction	508	Women's pregnancy period from a cohort	PPD	FFS-RF, SVM	Sensitivity: 69%, AUC: 0.78
[35]	Prediction	6558	A nationwide survey from the KoWePS	Onset depression in community-dwelling adults	–	Accuracy: 86.60%, sensitivity: 73.00%, specificity: 86.60%
[34]	Treatment	–	Escitalopram versus Electrical Current Therapy	tDCS and escitalopram	XGB	
[67]	Classification	8063	Chinese middle and high school students	–	LDA	Accuracy: 91.00%
[33]	Identification	31	fMRI	Dopaminergic enhancement	LR	
[68]	Prediction	122	EEG	Adult Patients	SVM	Accuracy: 82.40%, sensitivity: 79.20%, specificity: 85.50%
[69]	Evaluation	1000	BDI-II, China	Status of Chinese Recruits	DT	AUC: 0.734, sensitivity: 94.10%, specificity: 43.30%
[70]	Examine	276	–	Diabetes	Reinforcement learning	
[71]	Identification	1435	CBT, CID	CBT vs PCC	Elastic Net	RCSI: 62.50%
[72]	Identification	1500	NSSD	MDD in different mental health services	RF	accuracy: 73.40%
[73]	Differentiation	162	PROTAHBI, PROTHUM	Unipolar and bipolar depression	SVM-Kernel	AUC: 0.69, sensitivity: 62.00%, specificity: 66%
[74]	Identification	–	TSST-C	Speech detects anxiety	LR, SVM-Kernel, RF	Accuracy: 80.00%, sensitivity: 54.00%, specificity: 93.00%
[75]	Prediction	47	Actiwatch, EMA	–	LR	Accuracy: 91.00%, precision: 92.90%, specificity: 94.00%, AUC: 0.960
[31]	Predict the treatment	283	Depression-focused Internet Intervention	Internet interventions as effective treatments for adult depression	RF	Gain: 8.0%, 95% CI 0.8–15
[76]	Discovery	610	PHQ	Longitudinal patterns	ANN	8–13% of the patients have suicidal ideation in the improvement of their PHQ-8
[77]	Age estimation	78	IXI, OASIS	Brain Age	Relevance vector regression	
[78]	Recognition	–	Lanzhou University Second Hospital	–	SVM	Accuracy: 84.86%

Table 3 (continued)

Reference	Objective	Subj	Dataset	Domain	Classifier	Performance measures
[79]	Prediction	2388	Posts in daily life group	PPD	LR, SVM, MLPs	91.70
[80]	Identification	84,317	INPC	Advanced care	RF	AUC: 0.944, sensitivity: 83.91%, specificity: 92.18% Accuracy: 78.60
[81]	Prediction	–	8-channel EEG pre and post TMS in resting stage	Comorbid posttraumatic stress disorder	SVM	–
[82]	Drug discovery	–	CMap, ATC, MEDI-HPS	Repositioning	SVM, RF, GBT	Accuracy: 66.00%
[83]	Prediction	356	NESDA	Psychological and Biological	LR	Accuracy: 64%, 95% CI
[84]	Prediction	90	MI-ANXDER, Sweden	iCBT	SML	0.61–0.68, $P < 0.001$
[85]	Prediction	174	–	Placebo vs antidepressant medication vs psychotherapy	DT, RF, LR	–
[86]	Prediction	81	PET	rs6295 gene polymorphism on serotonin-1A receptor distribution	RF	Accuracy: 72.50%
[87]	Differentiation	57	–	Anxiety vs major depression	SVM	Accuracy: 90.10%
[88]	Detection	–	Non-institutionalized U.S. civilians	Clusters through graphing	SOM	$P < 0.001$
[89]	Prediction	–	OPD in the Clinical Center of Nis Serbia	Breast cancer patient	ANN	RMSE: 0.853, R^2 : 0.5345, r : 0.7241

Total number of the subjects = 513,767; mean \pm SD = 10,931.212 \pm 35,624.372

RF random forest, SVM support vector machine, LR logistic regression, DT decision tree, EHRs electronic health records, HC health control, MDD major depressive disorder, BD bipolar disorder, fMRI functional magnetic resonance imaging, Ko WePS Korean Welfare Panel Study, iDCS transcranial direct current stimulation, CHS Clalit Health Services, PPD post-partum depression, CART classification and regression tree, AB AdaBoost, GB gradient boost, XGB extreme gradient boost, KNN K-nearest neighbor, NSSD National Survey on Symptomatology of Depression, PHQ Patient Health Questionnaire, MLPs multilayer perceptrons, TSST-C trier social stress task for children, iCBT internet delivered cognitive behavior therapy, SML supervised machine learning, INPC Indiana Network for Patient Care, CMap connectivity map, ATC anatomical therapeutic chemical, MEDI-HPS medication indication resource high precision subset, CBT cognitive-behavioral therapy, PCC Person-Centered Counseling, BDI-II Beck Depression Inventory-II, GLM generalized linear model, CHS Clinical High-risk Syndrome, ROD recent-onset depression, NESDA National E-Governance Service Delivery Assessment, TMS transcranial magnetic stimulation, OASIS open access series of imaging studies, PROTHUM Programa de Transtornos de Humor, PROTAHBI Programa de Transtornos Bipolarize, FFS-RF random forest-based filter feature selection, iSPOT-D International Study to Predict Optimized Treatment-in Depression, IMD immunomodulatory imide drug, STEPd Stellaria Pallida, EHR electronic health record, WCM Weill Cornell Medicine, CDRN Clinical Data Research Network

Table 4 Previously published study related to deep learning on depression based on the number of the subject, method, dataset, data type, and objective

References	Subject	Method	Dataset	Data type	Objective
[14]	29	Deep learning, Neuropsychological test	Community-dwelling, North East, England	Speech	Detection
[15]	–	Combination of CNN and LSTM	University of New Mexico	Signal	Detection
[40]	81	NLP	Trauma survivors, New York	Image, Video	Classification
[12]	13,993	BERT, RoBERTa	Weibo, China	Text	Prediction
[11]	34	CNN, STFT, Wavelet	EEG dataset	Signal	Diagnosis
[90]	2757	NN, T-test	Data from CO-MED	Text	Treatment
[13]	51	2D CNN, Graph theory	Lanzhou University	Signal	Recognition
[38]	30	2 D CNN, LSTM	EEG dataset	Signal	Diagnosis
[37]	19,725	Graph theory, T-test	NHANES and K-NHANES	Image	Identify
[36]	1190	FCN, Chi-square test, F-test	ADE20K, China	Image	Examine
[39]	19	SVM, LR, KNN, DNN, Deep-CNN	fMRI dataset	Image	Impact
[91]	8	MFNNs, T-test	The National Health Research Institute, Taipei Veterans General Hospital	Genetic	Prediction
[92]	–	PS-CS	Reddit	Mathematical	Prediction

Total number of the subjects = 37,917; mean \pm SD = 3159.75 \pm 6285.57

FCN fully convolutional neural network, *SVM* support vector machine, *LR* logistic regression, *KNN* K-nearest neighbor, *DNN* deep neural network, *EEG* Electroencephalogram, *fMRI* functional magnetic resonance imaging, *NLP* natural language processing, *CNN* convolutional neural network, *MFNNs* multilayer feedforward neural networks, *NN* neural network, *BERT* bidirectional encoder representations from transformers, *RoBERTa* robustly optimized bidirectional encoder representations from transformers pertaining approach, *STFT* short-time Fourier transform, *LSTM* long short term memory, *PS-CS* particle swarm-Cuckoo search

and neuron excitability increased in males [106]. These transcriptional modifications play a role in major depressive disorders (MDD) and can be studied further to develop anti-depressive medications accordingly. A study conducted on Chinese university students showed that high sugar intake, gender, grades, and complaints of stress and anxiety were associated with depression [107]. The presence of injury, a high-fat diet, and depression was associated with anxiety and stress. This study concludes that stress, depression, and anxiety are correlated to causing psychological distress [108].


Effects of depression on the brain and cardiac systems

Clinical depression is an adverse form of continuous stress. Stress negatively impacts human behavior and mental health. Persistent and prolonged stress leads to hippocampus function impairment because of the increased glucocorticoid levels [109]. Constant pressure leads to the neural scar effect's gradual loss of hippocampus volume. Hippocampus impairment aggravates stress-induced memory deficit and cognitive impairment [110]. It is vulnerable and targets part of the brain in depression. It can result in neurofibrillary tangles and global ischemia. Repeated stress causes dendritic atrophy in the CA3 region [111]. A study was conducted

by Samuel et al. [112] in which they concluded pre-and post-synaptic effect of depression on neurons reduces the number of NMDA receptors activating the TPA/plasmin system. TPA/plasmin system acts as a mediator in the devastating impact of chronic depression on hippocampal function at the neural level was on stressed mice. Others were normal and showed significant loss of hippocampal volume in stressed mice within a ten-day tenure. Normal mice brain was not affected by the environment provided and no significant change was noted in the total brain volume of both groups; another conclusion was that the same type of stress has an asymmetric impact on both sides of the hippocampus [113]. In depression, the left hippocampal part has more volume reduction than the right one [109].

Histopathological studies done postpartum on people who were depressed in life showed cortical and subcortical region alterations. Those areas were functionally disabled. Major depression disorder can be diagnosed by the neuroimaging of the orbitofrontal region of the brain [114], where the thickness of the cortical is reduced, and the density of neuron and glial cells are decreased [111]. The progressive histopathological loss because of depression causes traumatic brain injury, a significant cause of disability and death around the globe [115]. Depression increases the number of reactive oxygen species, causing mitoc stress in the body that lowers the antioxidants [116]. The significant effect of oxidative


Fig. 3 Relationship between psycho-neurological human behavior such as stress, anxiety, and depression



stress is seen in the brain, with a high need for oxygen, fat, and low antioxidant levels [117]. The increased oxidative stress because of depression causes neurodegenerative disorders. Pro-oxidants such as copper are found in the free form more and less in depressive patients, affecting neuronal excitability and functioning. The copper radical also hinders neurological signal transmission and is negatively influenced as they alter the cortical glutamatergic neurotransmission [118]. Oxidative stress caused by depression is also linked with cardiac hypertrophy, leading to heart failure because of the increased free oxygen species and decreased antioxidant defense [119]. Studies suggest that heart failure resulting from myocardial infarction is associated with antioxidant deficit and myocardial oxidative stress [120]. ROS is linked with arrhythmic conditions, leading to cerebrovascular dysfunction and myocardial infarction. Another study conducted on patients with acute myocardial infarction showed that reactive oxygen species are directly connected with the pathogenesis of atherosclerosis, causing acute coronary artery disease and causing aggravation in the ischemic condition of the heart [121].

Major depression causes multiple health problems. Two subjects were studied for four years in a cohort study, one group with cardiac disease and depression and another group with depression but not having cardiac diseases. It was concluded that cardiac mortality increases in depressed individuals in both groups. Another study states that even if the social and environmental factors are still minor and major depression is the causative agent of early death, minor depression is more associated with elderly patients [111, 122]. Physical and emotional stress sometimes causes reversible cardiomyopathy associated with acute onset of cardiac pain and abnormal cardiac wall motion. Stress cardiomyopathy is sometimes confused with coronary heart disease, but the enzymatic levels such as troponin T and troponin I increase, becoming a risk of heart attack [123]. SCM is also found to elevate other cardiac enzymes such as plasma catecholamine and neuropeptide levels, which can cause myocardial stunning and brain injury [124]. Figure 4 illustrates the impact of depression on the nervous and cardiac system. The hypothalamic-pituitary axis can be activated and neurohormones can be secreted as a result of alterations in the central nervous system (CNS), which can destabilize

Fig. 4 Impact of depression on the nervous and cardiac system



the sympathovagal balance. The progressive onset of coronary artery disease (CAD), plaque activation, and an acute episode can all be caused by immune system suppression and an increase in pro-inflammatory cytokine release [125].

Relation between oxidative stress, inflammation, and mitochondrial dysfunction in depression

Morava et al. [126] reported that chronic mild stress causes dissipation of mitochondrial membrane potential, inhibition of mitochondrial oxidative phosphorylation (OXPHOS), and ultrastructure damage of mitochondria in numerous brain areas plus the hippocampus, cortex, and hypothalamus. These findings conclude that mitochondrial dysfunction leads to brain energy impairment, and perhaps causes depression. Furthermore, studies have reported that patients who suffer from depression show reduced glucose utilization in the PFC, caudate nucleus, and anterior cingulate gyrus [127].

Activation of inflammatory, immune, oxidative, increased HPA-axis and nitrosamine stress paths have been observed in major depression as evident from many studies. Stress increases IL-1 β , TNF α , IL-6, and another pro-inflammatory cytokine. Mitochondrial damages are induced by the mitochondrial complexes I and IV suppression by TNF- α , a pro-inflammatory cytokine, and pyruvate dehydrogenase activities. In the brain, reactive oxygen species (ROS) production is increased by IL-6 stimulation and mitochondrial cytochrome *c* oxidase is inhibited by Nitric oxide, a potent inhibitor [128].

The other factor persuading the aetiology of depression is an inequity between ROS production and the antioxidant defense mechanism. Brain oxidative stress is increased in depression which lowers brain glutathione concentration, catalase, superoxide dismutase, and total antioxidant

capacity as reported in-vivo study in mice [129]. The core site of the cell's ROS production are mitochondria and extremely prone to oxidative damage. Proteins, lipids, oxidative phosphorylation enzymes and mtDNA are further disposed to oxidative impairment in mitochondria. Consequently, mitochondrial dysfunctions exacerbate oxidative stress, impairment of mitochondrial DNA (mtDNA) or deletions of mtDNA, increase in intracellular Ca²⁺ levels, changes in fission/fusion and mitochondrial morphology and lastly leads to neuronal death. Additionally, mitochondrial dysfunction is conceded by energy demand upsurge for the cellular repair process and in this way damage to mitochondria leads to more damage [128].

Effects of depression on gene, protein, and hormone

Depression is a multifactorial and multi-genetic health problem. Several genetic mutations are seen that are connected to depression. The Association between genetic variants, mood-related traits, and medication of environmental factors is shown in Table 5 [130]. The hypothalamic-pituitary-adrenocortical system (HPA) plays a significant role in the cause and development of depression [131]. HPA system is hyper-activated in depression by the part of corticotropin releasing hormone (CRH) and glucocorticoid binding receptor system found in the hippocampus. HPA system dysregulation causes cognitive impairment in depressed people [132]. Depression is associated with CVD, but the mechanism is unclear. A study claimed depression increases C reactive proteins in the body, which causes systemic inflammation resulting in CVD risk [133]. Inflammation and depression have a bilateral relationship, as depression enhances the activation of CRP, IL-1, and IL-6, which is positively associated with inflammation and increased BMI and

Table 5 Adapted from clinical evidence-based gene-environment interaction model of depression

Parameters associated with mood influencing	Protein	Gene
Trait anxiety, neuroticism	SERT, CB1	SLC6A4, CNR1
Coping with stress	5-HT1A, 5HT1B	HTR1A, HTR1B
Hopelessness	TPH2	TPH2
Rumination	CERB1, GIRK, BDNF	CREB1, KCNJ6, BDNF
Impulsiveness	5-HT1A, COMT	HTR1A, COMT
Anxiogenic and depress-genic effects of Medication	SERT, CB1	SLC6A4, CNR1
Effect of negative life events on mood and depression	SERT, CB1	SLC6A4, CNR1
Susceptibility towards seasonal changes, depression	5-HT2A	HTR2A

vice versa [134]. Cortisol is secreted at the hormonal level, and the hypothalamus pituitary-adrenal axis (HPA) is also hyper-activated in depression. An increase in cortisol levels makes individuals more vulnerable to mood disorders. Estrogens are a group of hormones that are associated with women reproductive health. In depression, estrogen levels are negatively correlated. Decrease in estrogen hormones in female leads to depression and anxiety, whereas increasing estrogen levels in women helps reduce depression symptoms [135, 136]. When cortisol levels are high, it works on the amygdala producing simultaneous responses, which later are shifted to the hippocampus to rationalize the situation. This transition because of depression is dependent more on an individual's cognitive processing before the onset of puberty [137].


Noradrenaline and ACTH show a more rapid increase in acute stress than cortisol levels. An increase in ACTH levels elevates cortisol secretion, and it also causes fatty tissue deposition in the body. Acute stress also promotes leptin and IL-6 these parameters can increase the weight of the depressed person [136]. In major depressive disorder patients, depression affects the peripheral inflammatory markers activation such as cytokines, interleukins, chemokines, and tumor necrosis factor-alpha further affects the blood circulation and parts of the brain such as the amygdala. Moreover, in women, elevated estrogen levels aggravate mood swings and stress conditions. Estrogen also affects the mechanism of action of antidepressants and the body's response to them [138]. In depression, it is evident that mitogen-activated protein kinase, particularly ERK, is down-regulated in depressed individuals at the hippocampus, and prefrontal cortex levels along with the reduction of BDNF and CREB activity [99]. The gut microbiome is an important component of the microbiota-gut-brain axis (MGBA), which influences the brain and behaviour. Disturbance of the gut microbiome affects tryptophan (TRP) levels. TRP is an essential amino acid and there are two major TRP metabolism pathways in the brain and peripheral systems: > 95% of TRP is converted into kynurenine (KYN) and its breakdown products, which are involved in inflammation, immune response, and excitatory neurotransmission, while a small portion of TRP is used

to produce transmitters like 5-HT. An earlier investigation revealed that the enzyme IDO1 was involved in the KYN pathway and that patients with depression had higher plasma KYN/TRP ratios. TPH2 is an isoform of TPH that regulates the brain's production of 5-HT. According to studies, TPH2 aberrant expression can raise a person's risk of suicidal thoughts and severe affective disorder score [139]. Another gene that plays a significant role in depression aggravations is 5 HT1A. Due to its crucial significance in the autoregulation of the functional activity of the brain's 5-HT system, the 5-HT1A receptor draws particular attention. Overall, 5-HT1A signaling reduces protein kinase activity and neuronal firing rate. The pre- and postsynaptic 5-HT neurotransmission implicated in mechanisms of sleep, stress response, appetite, sexual motivation, aggressive behavior, depression, and anxiety is powerfully regulated by 5-HT1A receptors. It has been demonstrated that genetically defined aggression is correlated with decreased 5-HT1A receptor mRNA expression in the midbrain, decreased 5-HT1A receptor density in the hypothalamus, frontal cortex, and amygdala, and lower 5-HT1A receptor functional activity [140].

Treatment and diagnosis of depression patients

Depression is one of the major health concerns faced by human beings worldwide. It is more prevalent in low-income countries and can trigger many other disabilities [141]. The effectiveness of treatment for depression is dependent on several factors such as differences in gender, comorbidities, behaviors, and socioeconomic conditions [142]. Multiple treatments are implied to reduce depression in human surroundings. From the beginning of the twenty-first century, nine major antidepressants have been introduced to treat depression. Newly formulated drugs are structurally different from previously existing medicines such as monoamines. Depression has multiple factors, and the treatment plan should be according to them. It is essential first to rule

Fig. 5 Treatment of depression based on different techniques



out the underlying cause of depression. Monoamine oxidase inhibitors are effectively in depressed patients who do not respond to tricyclics [143]. Estrogen therapy could be done in women facing prenatal or postnatal depression and premenopausal stages [142]. Cognitive-behavioral therapy is also used to treat depression. An experimental study was conducted to compare behavioral activation of cognitive therapy and behavioral therapy and skills to control automatic thoughts without CT. Results showed that both treatments are equally effective, but the attributional style was predictive only in BA, not CT. Psychotherapies are found most effective even in pandemic times, as provided by the e-counselling strategy [144]. Exercise or physical activity probably has a central effect on depression via an increase in the release of β -endorphins, in the accessibility of brain neurotransmitters such as dopamine, serotonin, and noradrenaline, or in brain-derived neurotropic factors. Wu et al. [145] provided evidence for the effectiveness of Aerobic training in Parkinson's disease with depression patients had minimal physical and mental symptoms and improvement in their QoL and decrease in depressive symptoms. Aerobic exercise with a

public health dose of 17.5 kcal/kg/week energy expenditure is also effective in lowering the severity of depression [146]. Another study also claims that when physical activity is added to antidepressants in one's treatment, it shows more positive responses [147]. Multiple levels of treatments for depression can range from lifestyle modification, psychotherapy, anti-depressive medication, estrogen therapy, CBT to the use of AI. Treatments of depression based on different ways are summarized in Fig. 5.

The Unani medicine (USM) is a traditional complementary and alternative system of medicine for treating depression. It has holistic principles that support a practitioner in turning a diagnosis into a treatment plan and employs various techniques. It obeys a complete healing philosophy. Hence, in USM various therapies are available for curing the sickness as well as improving the patient's general health. There is rising evidence of the usefulness of herbal medicines in treating anxiety and depressive disorders. Psychotherapy, dietary treatment, or pharmacotherapy can be used alone or in combination to treat depression. Psychiatric diseases have been discussed in detail in Unani medicine, which identified numerous symptoms of mental

faculties due to the participation of vitiated humour, particularly yellow bile and black bile. Still, their symptoms are discussed under several headings such as melancholia, delusion, hallucination, insomnia, disorder of love, palpitation, etc. Avicenna recognized numerous mental illnesses including the disorder of love, which was defined as an obsessive disorder approaching severe depression [148]. In Arabic and Unani literature, anxiety has been described, while the word *psyche* is appended to anxiety to describe its psychological state. *Izterab Nafsan* means "concern, fear, and excessive pondering". It's also used to describe a stumbling block to routine tasks [149, 150].

As per the role of diet, there is another dietary element named as probiotic commonly found in yogurt that can be very helpful for depression patients. Probiotics' primary function in the treatment of depression is to modulate the gut microbiota to restore the balance of the gut's microorganisms. By encouraging the biotherapeutic activity of the advantageous microbiota and inhibiting the pathogenic action of the pathobionts, probiotics have a positive impact on human health [61]. A bacterium is the best option for a probiotic if it can penetrate the target organ, which is typically the intestines, endure numerous physiological stressors, including the shifting pH down the gastrointestinal canal, and stop the progression of the disease [62, 63]. The most popular microorganisms employed as probiotics are *Lactobacillus* spp. and *Bifidobacterium* spp. because of their wide range of health-promoting qualities. These bacterial species are well-known for their potential as antidepressants and for having good safety profiles. They have a modest pathogenic potential and hardly accelerate the horizontal spread of antibiotic resistance in pathogens [151].

Temperament is a unique condition in the USM of an individual that reflects metabolic, neuroendocrine, genetic, and some environmental balance at the optimal adjustment of function level [150]. The body's normal and healthy functioning depends on the harmony of certain temperament, and disruption in this state is the source of bad health, resulting in various medical states. Simple imbalance of temperament is defined as a change in the equilibrium of four qualities, namely warmth, coldness, moistness, and dryness. If this imbalance occurs at the level of body fluids/humour, it is defined as abnormal substantial temperament [149, 150]. Hippocrates' humoral theory is well known and his idea assumes that the body contains four humours expressed as sanguine, phlegmatic, choleric, and melancholic based on the humour present in them. Each individual is expected to have a different humoral constitution that reflects their overall health. Any change in this has an impact on his overall health. Psychic, vital, and digestive faculties are the three major faculties in Unani medicine to manage the human body and are unique to a given tissue or organ, and they are responsible

for the organ's distinct tasks. Nutrition, growth, and reproduction are all addressed by digestive power/faculty. Brain is said to be the seat of psychic or mental power, which is concerned with sensory, intellect, and motor functions. These are perceptive/cognitive faculties, of which there are two types: external perceptive power and internal perceptive powers. Internal perceptive faculties are connected with the intellectual functioning of the brain. In contrast, sensory function is external perceptive power and also includes five external senses such as hearing, vision, smell, taste, and tactile sensation. Psychiatric issues are addressed in depth in the psychiatric diseases in Unani literature. Imaginative power, thinking power, and memory were described by Haly Abbas (*Majusi*) [150, 152].

Traditional Unani medicine describes that the brain is at the center of these abilities, which allows them to plan and execute functions of imagination, reasoning, and memory. The change in quantitative or qualitative of humours predominantly morbid black bile and loss of continuity leads to an imbalance temperament of the brain and act as a risk factor for psychiatric, mental illnesses caused by disturbance of mental faculties [153]. Psychiatric diseases produce depression, grief, hallucination, mood swings, delusion, sadness, negative thoughts, etc. These symptoms are surmised as depression. Forgetfulness and dementia (Alzheimer's disease) arise in old age due to changes in the brain, morbid phlegm accumulation in the brain whereas excessive dryness causes insomnia [154]. Pneuma movement outward or inward is seen in various emotions for example in anger the pneumatic moves sudden and outward, gradual and outwards as in happiness, in fear, sudden and inward and gradual and inwards as in sadness [3]. Internal perceptual capacities are five in number includes faculty of composite sense, imagination, memory, and ideation powers [154].

Faculty of composite sense is the capacity to convert all sensations, react to this form, and combine their shapes. Memory power is responsible for the retention and memorizing of the shapes of things. Imagination power is defined as the perception of thinking. Ideation and memory power help to perform imagination power. Imaginative power is concerned with creating abstract concepts, imagination, and thoughts. They were only divided into three categories by Haly Abbas and other physicians: thought, thinking and memory processes are considered as a single faculty.

The brain is classified into three functional parts by Unani physicians: forebrain, midbrain, and hindbrain. The forebrain has the processes/power of the thought, the midbrain thinking and hindbrain memory. If a disease affects the entire brain, all three processes and functions become impaired. If the condition is limited to a particular brain area, the deficiency will only affect that faculty. Psychiatric disorders are classified as depression/ melancholia, insomnia, palpitation, delirium, insanity and other terms in the Unani medical

system [155]. Avicenna has recommended the use of medications that increase the substance of the brain, purify the brain, sedative, brain tonics, and medications that promote memory, heart tonic, brain stimulants, and memory enhancers. Blood purifiers purify the blood to some extent. The medications that stop producing and prevent gaseous material migration towards the brain from other body organs may potentially be used in the treatment if necessary [3]. The following are the therapy principles:

- Except for sanguine humor, concocting the affected humour, primarily through concoctions followed by purgatives for morbid matter evacuation, and secondarily venesection.
- Using medications such as moisturizer, alternatives of temperament, therapy like massage, exercise, and exhilarants to relieve tachycardia, palpitation, thirst, and overall coldness.
- Using psychiatric counselling and administering brain tonics.

Treatment care plan is determined by the humour that is impacted. Depression is frequently produced by the combustion of one of the four senses of humour, which then transforms into the black bile variety; as a result, the afflicted humour, i.e., the predominance of black bile throughout the body, must be removed. Depending on the patient's condition, venesection of the saphenous or cephalic vein is performed until the running blood's blackish hue and viscosity persist. Following venesection, black bile purgative is advised such as medicated decoction of roots of *Papaver somniferum*, *Ziziphus sativa*, *Cordia latifolia*, *Andropogams haenarthus*, *Caparis spinosa* root wall, *Rubia cordifolia*, each 25 gm, and given with sweet almond oil (*Roghan Badam Shirin*) in a dose of 70 ml for 7–10 days continuously [150, 152]. Evacuation is produced with semisolid preparation (*Jawarishat*), which consists of *Cuscuta reflexa*, *Terminalia chebula* unripe fruit, and *Boswellia serrata*. Following venesection, lamb flesh cooked with *Cucurbita maxima*, *Spinacia oleracea*, and dressed with almond oil, as well as half-boiled egg yolk with *Sharbat-i-Banafsha*, can be advocated to produce moistness in the blood. As a purgative, *Habb-i-Ustkhudoos* (*Lavandula stoechas*) can be used. If purgation is required, *Cuscuta reflexa* infusion and *Lavandula stoechas* with cow's churned milk should be provided [156].

Mechanism of action of natural bioactive molecules in medicinal plants for depression

Medicinal plants comprise many natural bioactive compounds useful in psychiatric disorders (anxiety, depression, etc.) as they possess antidepressants, nootropic (cognitive

enhancing), anxiolytic, hypnotic, sedative, antioxidant, and analgesic potential activities. The versatile cellular mechanism of action of these plants involves stimulating CNS activity or sedating and adaptable endocrine system's healthy function. Specific plant secondary metabolites such as tannin, phenolic compounds, and alkaloids bind to neurotransmitter/neuromodulator receptors acts through general function and alteration in neurotransmitter synthesis. Other traditional properties such as "adaptogenic" and "tonic" activities are hypothesized to augment adaptation to exogenous stressors through multifaceted effects on the endocrine system and neurochemistry [157]. Monoamine oxidases (MAOs) are localized on the mitochondrial outer membrane and they are Flavin adenine dinucleotide (FAD) co-factor-dependent enzymes. These enzymes catalyze the oxidation of endogenous and xenobiotic monoamines. Thus, MAOs modulate the levels of monoamine neurotransmitters and play a potential role in the central and peripheral nervous system. MAO-A and MAO-B are two isoforms that are present in most mammalian tissues. Monoamine oxidase MAO inhibitors (MAOIs) inhibit the activity either of MAO-A or MAO-B [158]. Antidepressants are MAO inhibitors of type A (MAOI-A). Phytoconstituent flavonoids (catechin and quercetin) inhibit MAO. Quercetin inhibits MAO-A. "Flavonoids activated upstream MAPK–kinase–kinase, inhibited oxidative stress-induced apoptosis, and prevented Jun N-terminal kinase activation". Catechin increases serum BDNF. Polyphenols, the second metabolite in the plant material acts on TrkB and TrkA expression and neurogenesis are amplified which results in neuroprotection and antidepressant potential [159]. Tannins act as antioxidants [160]. It is supported that the energy metabolism of mitochondria might have an antidepressant activity [161]. Several Unani plants extract and natural products such as *P. somniferum*, *Z. jujube*, *S. nigrum*, *B. monnieri*, *C. sativa*, *T. terrestris*, *W. somnifera*, *V. officinalis*, *Chamomilla officinalis*, *Echium amoenum*, etc. have been examined and screened for their possible neuro pharmacological actions in diverse animal models including mice and rats [162]. A study reported that black cohosh, chaste berry, passionflower, chamomile, lavender, and saffron seem to be beneficial in mitigating depression with favorable risk–benefit profiles compared to standard treatments [163]. Numerous human clinical trials provide initial positive evidence of the antidepressant properties of *C. sativus*, *E. amoenum*, and *R. rosea*. However, they concluded that watchfulness is suggested when interpreting the results as numerous studies have not been replicated. Furthermore, in vitro and in vivo evidence of several herbs are currently unexplored in human studies [157].

Z. jujube seeds, leaves and fruits have sedative, hypnotic, and anxiolytic actions. It contains phytoconstituents such as *triterpenic acids*, *flavonoids*, *phenolic acids*, *nucleosides*, *saponins*, *cerebrosides*, *vitamins*, and total sugars.

Its chemical compounds are *Zizybeoside I* and *II*, *Zizyphus saponin I* and *II*, *Jujubasaponin IV*, *Swertisin*, *Lotoside I* and *II*, *Chryseoriol*, and *Quercetin* [164]. In the mice model, *B. monniera* exhibited antidepressant activity [165]. *B. monnieri* plant is reported to have anxiolytic, antidepressant, antiepileptic, and anti-parkinsonism activities. It contains phytoconstituents such as alkaloids (nicotine, bacosides A & B, Brahmin, and herpestine), saponins (monnierin and her-saponin), flavonoids (apigenin and luteolin), and sterols like beta-sitosterol and stigma-sterol, proven for neuro pharmacological activities. *T. terrestris* leaves and the whole plant are proven for anxiolytic, antidepressant and sedative activities. Its phytoconstituents are flavonoids, saponins, alkaloids glycosides, and tannins. The chemical compounds present in *T. terrestris* are *quercetin*, *stigmasterols*, *rutin*, *tigogenin*, *neotigogenin*, *ruscogenin*, *cafeoyl*, *kaempferol*, *tribulosid*, *chlorogenin*, *terrestribisamide*, *Beta-sitosterol*, *norharmane*, *harmane*, and *tribulusterine* [166]. Similarly, *W. somnifera* has been reported to have anticonvulsant, antidepressant, anxiolytic, and anti-Parkinson actions, mostly due to the presence of *sitoinosides VII–X*, *withanolides*, and *withaferin-A* [167]. Müller et al. [168] use 2500 participants with depression, reported the combination of valerian (600 mg) and St John's-wort (600 mg) showed improved effects than each of them alone. *Valeriana officinalis* (valerian) acts as a partial agonist on the 5-hydroxytryptamine 2A receptor and the γ -aminobutyric acid (GABA)-A receptor comparable to benzodiazepines and boosts melatonin release thereby having antidepressant action. The valerenic acid and valepotriates, natural bioactive molecules of valerian root are accountable for their above mentioned application [169]. Amsterdam et al. [170] reported in an RCT on 57 patients that chamomile capsules (220 mg/dl) for 8 weeks significantly decreased the depression score in the chamomile than in the placebo group. Women during the postpartum period who consumed chamomile tea reported significant improvement in quality of sleep and depression in a controlled trial [171]. Apigenin and quercetin are bioactive molecules in chamomile with antidepressant potential because they can modulate dopamine, norepinephrine, GABA messaging, serotonin and controls hypothalamic pituitary adrenal (HPA) axis activity, and inhibits monoamine oxidase (MOA) enzyme action [170]. Sayyah et al. [172] reported *E. amoenum* (borage) (375 mg) showed significant antidepressant activity than placebo in a 6 weeks RCT. Rosmarinic acid and the sinine are the bioactive molecules were identified in Borage [173]. Some studies on borage recognized the role of oxidative stress in the anxiety of rodents. According to this, it has been shown that induction of oxidative stress in mice occurs at the same time as anxiety. *E. amoenum* has antidepressant, anxiolytic, anti-obsessive-compulsive, anti-inflammatory, antioxidant, and analgesic properties. The functional mechanism of *E. amoenum* perhaps depends on γ linolenic acid (GLA) [174].

Flowers of *E. amoenum* have GLA and anti-inflammatory and antioxidant properties. Cyanidin 3-glucoside is the most common anthocyanin present in the *E. amoenum* petals that has neuroprotective action and has routinely been used as an antidepressant and anxiolytic medicine in Asia [175]. *Lavandula* spp. is potentially useful in depression, anxiety and somatic tension. In various studies in animal models, anxiolytic activity has been proven. Lavender acts through GABA modulation (based on volatile constituents) [162]. An RCT confirmed that lavender tincture with imipramine was more effective than lavender alone in mild to moderate depression [176]. Other studies confirmed that *L. angustifolia* oil and Linalool had antidepressant and anxiolytic potentials in experimental animal models. viz., modulates both dopaminergic and serotonergic pathways, and improves the signaling. Another study established that lavender essential oil exhibits dose-dependent specificity for NMDA receptor [177]. Nikfarjam et al. [178] confirmed in an RCT that *L. officinalis*, as well as venlafaxine, were effective in major depressive disorder. Another double-blind RCT study showed that *M. officinalis* and *L. angustifolia* had similar effects to fluoxetine in mild to moderate depression [179]. Liu et al. [180] reported that *Rhodiola rosea* extracts in the hippocampus raise the 5-HT level, promote the proliferation of neural stem cells, and repair the damaged neurons in depressive rodent models. Rhodioloside a chemical compound present in *R. rosea* potentially inhibits stress-induced p-SAPK/p-JNK signaling pathways, showing its anti-depressant activity. *Nymphaea lotus* and *N. Alba* (Niloufer) flowers have anxiolytic, antidepressant, antioxidant, and sedative properties.

The seed extract of *C. sativum* demonstrated antidepressant-like activity by interacting with adrenoceptors, GABAergic receptor and dopamine D2 receptor thereby increasing norepinephrine, dopamine and decreasing GABA levels in mice brains [181]. The whole plant of *C. sativum* L. (Kishneez) exhibited antianxiety, anti-epileptic, antioxidant, and anti-inflammatory properties. In the animal models of anxiety, it improved exploratory activity and restored monoamines and GABA levels, reducing excitotoxicity levels of glutamate in the hippocampus region. It contains linalool, limonene and myrcene molecules which exhibit anxiolytic activity [182]. Flower and root of *Viola odorata* Linn (Banafasha/Sweet Violet) exhibited anxiolytic, antidepressant, sedative, anti-inflammatory, and antioxidant properties. The *V. odorata* extract (100–400 mg/kg) reduced immobility time in both force swimming test (FST) and tail suspension test (TST) in male mice animal models. The bioactive molecules in *V. odorata* are delphinidin, P-coumaric acid, tocopherol, anthocyanin, violanin chloride, anthocyanin, rutoside, friedelin and beta-sitosterol [183]. Curcumin treatment exerted significant antidepressant activity that is equivalent to the SSRIs (fluoxetine and imipramine), renowned antidepressant drugs. In addition, it

also prevents hippocampal BDNF levels from diminution in stress animal models and comparable to imipramine. Curcumin upsurges dopamine levels in the animal model (rodents) and the brain significantly reducing the properties of agents that induce a decrease in dopamine and adrenaline concentration. Hence various researches during the past decade confirmed that curcumin can control the levels of the neurotransmitter (norepinephrine, dopamine, serotonin and BDNF) that are accountable for behavior and mood regulation [184]. Furthermore, curcumin reduces pro-inflammatory cytokines gene expression, downregulates ICAM-1 and MCP-1, suppresses NF κ B induction, procollagen type I, and HMGB1, cyclooxygenase-2, and tissue inhibitor of MP-1 and induces PPAR- γ and have an effect on inflammation [185]. Curcumin's bioactive molecule also possesses antioxidant activity that is interconnected which triggers many antioxidant enzyme actions including catalase, glutathione transferase, and heme-oxygenase-1 [186]. Khayat et al. [187] stated that neurotransmitters levels were increased by curcumin, as a result, improved premenstrual mood and behavioral symptoms and COX-2 enzyme were inhibited as a result reducing physical symptoms of menstruation. Crocin present in *C. sativus* inhibits dopamine and norepinephrine reuptake, whereas safranal inhibits the reuptake of serotonin through the NMDA receptor. *Allium sativum* is useful in neurodegenerative disorders instigated by oxidant-mediated brain cell mutilation, mainly Alzheimer's [188]. In the human brain, garlic intake perhaps inhibits β -amyloid protein (A β) aggregation. A preclinical study in ovariectomized rats exhibited significant antidepressant properties of garlic and black sesame present in the dietary supplement [189]. Garlic, possibly reduces brain oxidative stress, hence effective in anxiety and depression behaviors in diabetic rats [190]. In addition, antidepressant-like activity was proven in a preclinical study conducted in mice, which exhibited that garlic extract inhibited MAO-A and MAO-B [191]. Fruit of *Terminalia chebula* Retz exhibited antidepressant and anxiolytic properties in an animal model (rodent). A study confirmed that in premenstrual mood and behavioral symptoms in women in the luteal phase, serum BDNF levels are lesser. In PMS women, treatment with Zinc supplement causes a noteworthy surge in BDNF than placebo. It has antidepressant antioxidant, and anti-inflammatory activities. It also perhaps affects inflammatory markers i.e., hs-CRP and, consequently, improves psycho-behavioral premenstrual symptoms [188]. Moreover, Zn²⁺ has an inhibitory role at GABA-A receptors [192]. A study confirmed that zinc increases the mRNA and BDNF protein in the hippocampus. It induces the MMP that triggers TrKP, then leads cells to release pro-BDNF and convert to BDNF. BDNF helps in the differentiation and endurance of serotonin in the neuron. In the body, Zinc also has antioxidant action and is

hypothetical to counter the excess ROS and inhibits NADPH oxidase [193]. IL-10 effects on the brain and behavior and possess anti-inflammatory immune function and takes part in depression anxiety, and modulation of mood symptoms [193]. Vitamin D decreases inflammation and has antidepressant activity, as the action of 1, α , 25-dihydroxy vitamin D3 (1, α , 25(OH) 2D3) is mediated through Interleukins. Vit D3 impedes IL-12 production in activated macrophages. The preliminary action of 1, α , 25(OH) 2D3 is a cyclical downhearted regulation of IL-12B appearance at the beginning of inflammation, till it supports the immune rejoinder with a likely level. Moreover, a secondary action of IL-10 happens that switches off the IL-12B gene [193]. In addition, the rhizome extract also has a tranquillizing effect. Iron, zinc, magnesium, etc. micronutrients deficiency leads to depression. Polypody rhizome and wheat germ contains iron, zinc magnesium hence useful to reduce depression and other psycho-behavioral symptoms [194].

Evidence based studies of composite formulation

Sharbat-e-Ahmed Shahi is an antidepressant Unani compound formula used for depression and insomnia. One of the ingredients is *P. vulgare*, the investigators testified that this compound potentially increases the availability of tryptophan, a 5HT precursor in blood and brain. Hence this compound increases 5-HT in the brain and has anxiolytic and antidepressant actions in experimental rats [195]. *P. vulgare*, a bioactive molecule, phytoecdysteroids possibly influence the activity of the central nervous system because of GABA-A receptor neuromodulatory action and neurotransmitter metabolism effect partially (increases the synthesis of GABA and decrease the breakdown of acetylcholine), and antioxidant properties [196]. Yasir et al. [197] investigated the effect of *Sharbat Ahmad Shahi* on serum BDNF levels in mild to moderate cases of depression and concluded that the formulation improved the serum BDNF level in 20 diagnosed cases of depression. Urooj et al. [198] studied animal models (rodents) and confirmed the antidepressant activity of both *Majoon Najah* extracts and the traditional compound Unani formulation. They concluded that antidepressant activity of *Majoon Najah* was exhibited because of multiple constituents present in its ingredients that possibly interact with dopaminergic adrenergic, and serotonergic receptors to result in increased levels of dopamine, norepinephrine, and serotonin with reduced GABA levels in animal brains [199]. The ingredients of the compound formulation are *T. chebula* Retz, *T. bellerica* Roxb, *E. officinalis* Gaertn, *O. turpethum* Linn, *P. vulgare* Linn, *C. reflexa* Roxb and *L. stoechas* Mill. A preclinical study in mice showed *E. officinalis* Gaertn extract (Amla) had anti-depressant activity similar to imipramine

and fluoxetine [199]. Its anti-depressant potential was credited to inhibit MAO-A and GABA [199]. In an animal model (mice) *T. bellirica* aqueous and ethanolic extracts showed significant antidepressant-like activity by interacting with dopaminergic, adrenergic and serotonergic systems [200]. Koneru et al. [201] reported anti-depressant activity of *Itrifal Kishneezi*, a Unani compound formulation in Swiss albino mice, comparable with fluoxetine and imipramine. *Itrifal Kishneezi* contains *T. chebula*, *T. belerica*, *E. officinalis*, *C. sativum* clarified butter and honey. Zakerin's group in an experimental study on rats investigated the antidepressant action of a polyherbal syrup containing *E. amoenum*, *M. officinalis*, *L. angustifolia*, *Z. jujuba*, *A. capillus-veneris*, *G. glabra*, *F. vulgare*, *C. myxa*, *F. parviflora*, and *Alhagi* spp. Manna [202]. They confirmed that polyherbal syrup exhibited significant antidepressant activity and caused an increased in 5-HT and NA levels in the rat without any effect on BDNF [202]. Antidepressant-like activity of *G. glabra* L. was investigated in mouse models and researchers concluded that *G. glabra* antidepressant activity appears to be facilitated by the increase of brain dopamine and norepinephrine and the inhibition of MOA [202]. Singh et al. [203] investigated the antidepressant activity of *Foeniculum vulgare* (fennel) fruits methanolic extract in experimental animal models. And it is concluded that *F. vulgare* exhibited antidepressant effects through MOA inhibitory actions. In chronic stress, in adult male mice *A. capillus veneris* exhibited antidepressant action [204]. Aqueous extract of *M. officinalis* showed antidepressant properties similar to imipramine [205]. *Khamira Gawzaban Ambari Jadwar Ood Saleeb Wala* is reported to possess antidepressant activity in mice. This compound formulation contains *Paeonia emodi* Wall. ex Royle, *Althaea officinalis* L., *Borago officinalis* L. (Flower), *Melissa officinalis* L. Cocoon of *Bombyx mori* L., *Santalum album* L., *Delphinium denudatum* Wall. ex Hook & T, *Salvia haematodes* W., *Lallemantia royleana* Benth., *Borago officinalis* L. (Leaf), *Cheiranthus cheiri* L., *Coriandrum sativum* L., *Ambra grasea*, silver leaves, and gold leaves. In addition, in animal model mice *Khamira Gawzaban Ambari Jadwar Ood Saleeb Wala* also showed improvement in learning and memory function. *Sufoof Jawahar Mohra* exhibited significant antidepressant activity at 12 and 24 mg/kg in FST model [206]. Lee et al. [207] summarized the therapeutic benefits of phytochemicals such as curcumin, quercetin ferulic acid, carvacrol, proanthocyanidin, L-Theanine, and resveratrol in depression.

The phytochemicals and herbs' antidepressive properties have been related to various mechanisms including monoamine neurotransmitters, HPA axis, and neurogenesis/neurotrophic factors mechanisms. Completely seems to include the promotion of neuronal cell survival and differentiation and neuronal cell apoptosis inhibition. Phytomedicine application is a possible choice for depression treatment

where conventional drugs are not appropriate due to their low effectiveness and side effects. However, the investigator recommended that the safety and efficacy of above-mentioned phytochemicals for depression must be reinforced by clinical studies. Figure 6 summarizes the role of oxidative stress, mitochondrial dysfunction and inflammatory process in depression and actions of bioactive molecules of herbal medicines as antidepressant, antioxidant, and anti-inflammatory.

Depressive moods and episodes can be a barrier to exercise, so further studies suggest making exercise plans specifically for depressed patients [208]. Psychodynamic psychotherapy treatment is required for depressed individuals as they feel losing their self-esteem. Psychotherapy helps patients stay calm and at peace with their lives [208]. Age-specific treatments still need to be conducted. Probiotics are also good in improving the symptoms of depression [209]; probiotics from the food sources such as pickles, yoghurt, and fermented products can be added to the diet of depressing patients to reduce the episode frequency and improve the severity. The anxiety symptoms can also be reduced by Omega 3 fatty acid supplementation, as in depression, the omega-six is increased, and omega-three fatty acids are reduced [210]. It increases the severity of the disease. So, omega-three food sources such as olive oil and coconut oils can also be added to the patient's diet and supplements. The treatment for depression patients is inadequate in 50% of the cases, so a multistage treatment is proposed for depression [211]. The affected area will be studied first. Secondly, the target areas will be treated with novel antidepressants [211]. Based on the biomarkers involved, further treatment plans and diagnosis plans for depression should be made. Particular attention is required for the treatment plan of depression based on epigenetic and biochemical markers, as these markers can help target specific sites affected by depression. It is believed that such a treatment will be more effective and quick [212].

Digital help in depression is a new technique and an effective one in lowering the cases of depression. It does not require a person to visit a consultant's office, and it is both time and money-saving [213]. A suite of indelicate apps, easy to download on one's phone, offers interactive learning and psycho-educational tools. A pilot study showed positive impacts on lowering the frequency of depressive episodes [58]. The various type of treatment related to depression are mentioned in Fig. 6.

Discussion

In this review, we have integrated and reviewed the effects of depression on the human brain and cardiac systems in the




Fig. 6 Depiction of the role of oxidative stress, mitochondrial dysfunction and inflammatory process in depression and actions of bioactive molecules (rosmarinic acid, luteolin, apigenin, quercetin,

beta-sitosterol, anthocyanin, withanolides, withaferin-A, and valerenic acid are beneficial in depression) of herbal medicines as antidepressant, antioxidant and anti-inflammatory




Fig. 7 Network visualization based on a previously published article related to this study

relation between oxidative stress, inflammation, and mitochondrial dysfunction in depression. Further, the effects of depression on genes, proteins, and hormones in the human body were also reviewed with the major role of machine learning and deep learning in depression. In addition, we also retrieved data regarding preclinical and clinical studies conducted on various Unani single medicinal plants and composite formula plus concept for treating and diagnosing depression patients using Unani and the modern system of medicine. Further, the relationship between depression, stress, and anxiety was also comprehended.

Clinical Depression impacts the general well-being of an individual. Prolonged depression results in hippocampus atrophy, neural scars, and memory deficit. Depression affects CNS and other human body systems such as the cardiovascular, GI and reproductive systems. Oxidative stress caused by depression affects the heart, leading to cardiac hypertrophy, and decreased antioxidant defense can result in cardiac failure. As per the etiology of depression, several factors are highlighted in current reviews, such as genetic factors, hormones, HPA axis, and environmental factors [113]. Currently, depression is considered as the disease of the

century as its incidence is increasing in society. Multiple treatments are available for depressive disorders, but the effectivity varies by mean of gender, socioeconomic status and co-morbidities. The use of medicinal plants are considered as a therapeutic substitute for treatment with the no or minimal side effects and treatment of depression through the action of different chemical compounds present in the structure of plants [180]. In USM, the authentic classical texts surmised single as well as composite Unani formulations effective for the treatment of psychiatric disorders including depression. Single herbs bioactive molecules such as linalool, limonene, delphinidin, P-coumaric acid, tocopherol, anthocyanin, violanin chloride, anthocyanin, rutoside, friedelin, curcumin, beta-sitosterol, bacosides A & B Brahmin, herpes-tine, monnierin, hersaponin, apigenin, luteolin, and myrcene are useful to treat depression, and anxiety. In addition, composite Unani formulae showed the potent action in depression such as (*Sharbat-e-Ahmed Shahi, Majoon Najah, Itrefal Kishneez, Khamira Gawzaban Ambari Jadwar Ood Saleeb Wala, and Sufoof Jawahar Mohra*) are proven of their efficacy and safety in preclinical and clinical studies in depression and anxiety [195, 197, 198, 201, 206]. Affirmative effects of various Unani herbs and their active compounds such as *chamomile, M. officinalis, Z. jujube, S. nigrum, B. monnieri, T. terrestris, W. somnifera, sweet violet, terminalia, lavender, borage, saffron, turmeric, valerian, and Rhodiola rosea L.* in mild, moderate or major depression amelioration have been reported in preclinical and clinical trials [214]. The aforementioned Unani medicinal plants show antidepressant properties and have lesser side effects than synthetic drugs. Further, many of these herbs also have anti-inflammatory, antioxidant, sedative, anxiolytic and other properties. Hence, they have the potential to treat patients with depression. Furthermore, in clinical practice, the empirical Unani formulas have been proven to have superior efficacy than single drugs, perhaps due to their reciprocated detoxification and synergistic interactions. In a composite formula, the synergy of multiple herbs triggers the interactions between herbal molecules from versatile herbs. Other anti-depressant therapies include monoamine therapy [121], Estrogen therapy in females, and congenital behavioral therapies, which can help to increase the impact of medications and help to cure the depressive disorder. Lifestyle modification has been studied and proved to prevent many health problems. In the case of depressive patients, physical activity and a healthy diet are also proven as significant factors to reduce anxiety and depressive behaviors [215]. In the pathophysiology of depression, a major challenge is lack of an assimilated database together with all interactions among the pathological aspects across biological systems, though efforts have been made to recognize the specific interactions within the CNS [216]. The mechanisms of action as per data collected, it is established that the aforementioned medicinal plants

referred can modulate the brain signaling pathways responsibly for the symptoms of depression. This is accomplished with inhibition of the serotonin transporter protein or sensitization of serotonin receptors or inhibits MA, alterations in the transmission of GABAergic and/or glutamatergic transmitters, increase BDNF, effect on concentrations of serotonin in the synaptic cleft and act on dopamine. However, although these actions have been scientifically proven, considerable research is still required to confirm the safe usage of these mediators as herbal medicines in the substitute or adjunctive handling of depressive disorders [180, 217].

We designed a novel network visualization diagram based on the previously published data using *VOSviewer* [218] shown in Fig. 7. While, we compared the closest terms based on the network visualization techniques, published keywords, and our present study, mentioned in Fig. 8. This study will open a way to find relevant and significant work related to the depression. It would be helpful for researchers, academicians, scholars, scientists, and doctors to find out the exact work related to depression. Previously, many researchers have implemented network visualization techniques in different areas like premenstrual syndrome [49], insomnia disorder [219], bruxism disorder [220], motor imagery [27], augmented reality [221], stress [26], blockchain technology [222], and smartphone addiction [223]. In addition, some researchers used word cloud in the area of anxiety, premenstrual syndrome with oxidative stress and inflammation [49], motor imagery with deep learning [27], education with augmented reality [221], human stress with machine learning [26], cryptocurrency with blockchain technology [222], yoga with intelligence [47].

We compared our study with previously published reviews [224–228] mentioned in Table 6. We found that our study is a comprehensive effort for researchers, scientists, doctors, academicians, and scholars related to depression. It provides necessary details in multidisciplinary areas such as zoology, botany, chemistry, pharmacy, medical, psychology, food, medicine, computer, electronics, electrical, and engineering. It also covers the present, past, and future aspects to depression.

The feasibility of the results obtained from the implementation and computational point of view in the review article on depression, focusing on AI, genetics, hormones, and oxidative stress, along with detection, treatment, and effects, relies on several important considerations. First and foremost, the availability of high-quality and relevant data is crucial. The presence of comprehensive datasets comprising genetic information, hormone levels, oxidative stress markers, and depression-related data is essential for conducting robust analyses. The quality, size, and diversity of these datasets play a significant role in the reliability and generalizability of the results. From a computational perspective, the study must have access to sufficient computational power. Analyzing

EHR data alongside various other parameters could show accurate and robust outcomes in the prediction of stages of depression, the effect of treatment, and expected outcomes. Most of the studies has discussed the techniques of diagnosis which includes questionnaires that are conducted at the time of self-reporting and in extension to this there have been many multimodal approaches in practice, but the outcome is poor. In contrast to time constraints and effectiveness of diagnosis, we need to consider more robust techniques and multimodal approaches that will help patients, doctors and society.

Our survey discussed various studies conducted to understand depression on patients' overall quality of life. There are many challenges and gaps that can be addressed for future work starting by proposing a multimodal diagnostic approach to handle depression diagnosis. At the same time, we can think of designing new models for early diagnoses that help to increase the efficacy of treatment. The future prospects of depression research are filled with promise and potential. Researchers are actively exploring various avenues to deepen our understanding of depression and improve treatment outcomes. One key area of focus is the development of personalized medicine, where advancements in genetics and molecular biology allow for tailored treatments based on an individual's unique genetic and biological markers. This approach holds the potential to enhance treatment efficacy and minimize adverse effects. Additionally, the integration of AI and machine learning is revolutionizing the field of mental health research. AI algorithms can analyze large-scale data sets, including electronic health records, genetic profiles, and patient-reported outcomes, to identify patterns and predictors of depression. This enables the development of more accurate diagnostic tools and predictive models, which can assist healthcare professionals in making informed treatment decisions. Another emerging frontier is the exploration of novel therapeutic approaches beyond traditional medications and psychotherapy. Researchers are investigating alternative treatments such as transcranial magnetic stimulation (TMS), deep brain stimulation (DBS), and psychedelic-assisted therapies, which have shown promising results in treating depression. These innovative approaches offer new avenues for patients who have not responded well to conventional treatments. Moreover, the growing recognition of the mind–body connection has led to increased research on lifestyle interventions and holistic approaches. Techniques like mindfulness meditation, exercise, yoga, and nutritional interventions are being studied for their potential benefits in managing depression symptoms and improving overall well-being. Collaborative efforts between different scientific disciplines, including neuroscience, psychology, genetics, pharmacology, and technology, are further fueling advancements in depression research. This interdisciplinary

approach fosters a comprehensive understanding of the complex mechanisms underlying depression and opens doors to innovative treatment strategies. Overall, the future of depression research is bright. As scientific knowledge expands and technology continues to advance, we can expect to see breakthroughs in personalized medicine, AI-driven diagnostics, novel therapeutics, and holistic approaches. These advancements hold the potential to transform the field, improve patient outcomes, and bring new hope to individuals living with depression.

Conclusion

This study highlights the relationship, classification, identification, recognition, effect, detection, and treatment aspects such as traditional to emerging technologies related to depression. It has also provided the research gaps and future directions for the readers to work on depression in any of the research interests like using AI in medical. Further investigation can be done to provide necessary details in a single study related to other psycho-neurological human behaviors such as anxiety and stress. Consequently, vigorous methodology, pharmacological good manufacturing practice and the use of bioengineering to certify bioequivalence of product, smart health, and bigger application of genetic knowledge, is still required to endorse assurance in this area. This manuscript has unveiled the limitations of existing treatments and approaches. It has also provided the detailing of challenges faced in rehabilitation and treatment of Depression. Enlightening the aspects of AI that can be used in better diagnosis and treatment of depression this write-up has summarized all major tools and machine learning methods. Using the present techniques and suggested future advancements of AI can further be improved and studied in the healthcare sector especially in case of depression.

Acknowledgements We would like to thank Prof. Naseem, Prof. Singh, Prof. Lai, Prof. Chandel, Prof. Ansari, Prof. Siddiqui, Dr. Saba, Ms. Parveen, Ms. Jianning, Ms. Pillai, Ms. Yitian (Claire) Zhang, Fangyuan (Tiffany), and Shuyun (Jane) Zhang for their support, help, and appreciation. We also acknowledge the IoT Research Center of Shenzhen University for providing the facilities for this study.

Author contributions MBBH, FA, FM, and AS: conceptualization, methodology, writing-original draft, investigation, project administration; software, validation, and resources; AYM, IG, MS, and WA: data curation, validation, methodology, formal analysis, and writing-review and editing; SMAI, AAB, and ITD: supervision, conceptualization, visualization, investigation, resources, and writing-review and editing; KW: data curation, formal analysis, software, and writing-original draft. All authors have read and agreed to the published version of the manuscript.

Data availability statement Not applicable.

Declarations

Conflict of interest None.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

References

- Gorlova A, Svirin E, Pavlov D, Cespuglio R, Proshin A, Schroeter CA, Lesch K-P, Strekalova T (2023) Understanding the role of oxidative stress, neuroinflammation and abnormal myelination in excessive aggression associated with depression: recent input from mechanistic studies. *Int J Mol Sci* 24:915. <https://doi.org/10.3390/ijms24020915>
- Xiao X, Zhu X, Fu S, Hu Y, Li X, Xiao J (2020) Psychological impact of healthcare workers in China during COVID-19 pneumonia epidemic: a multi-center cross-sectional survey investigation. *J Affect Disord* 274:405–410. <https://doi.org/10.1016/j.jad.2020.05.081>
- Waseem A, Akram U, Ahmad W, Fazil M (2020) Medicinal plants used for treatment of psychiatric disorders in Unani medicine. *Acta Sci Neurol* 3:11–17. <https://doi.org/10.31080/asne.2020.03.0189>
- Hasan MR, Paul BK, Ahmed K, Mahmud S, Dutta M, Hosen MS, Hassan MM, Bhuyian T (2020) Computational analysis of network model based relationship of mental disorder with depression. *Biointerface Res Appl Chem* 10:6293–6305. <https://doi.org/10.33263/BRIAC105.62936305>
- Várkonyi D, Török B, Sipos E, Fazekas CL, Bánrévi K, Correia P, Chaves T, Farkas S, Szabó A, Martínez-Bellver S, Hangya B, Zelena D (2022) Investigation of anxiety- and depressive-like symptoms in 4- and 8-month-old male triple transgenic mouse models of Alzheimer's disease. *Int J Mol Sci* 23:10816. <https://doi.org/10.3390/ijms231810816>
- Galts CPC, Bettio LEB, Jewett DC, Yang CC, Brocardo PS, Rodrigues ALS, Thacker JS, Gil-Mohapel J (2019) Depression in neurodegenerative diseases: common mechanisms and current treatment options. *Neurosci Biobehav Rev* 102:56–84. <https://doi.org/10.1016/j.neubiorev.2019.04.002>
- Prisnie JC, Sajobi TT, Wang M, Patten SB, Fiest KM, Bulloch AGM, Pringsheim T, Wiebe S, Jette N (2018) Effects of depression and anxiety on quality of life in five common neurological disorders. *Gen Hosp Psychiatry* 52:58–63. <https://doi.org/10.1016/j.genhosppsych.2018.03.009>
- Bekhat M, Neigh GN (2018) Sex differences in the neuro-immune consequences of stress: focus on depression and anxiety. *Brain Behav Immun* 67:1–12. <https://doi.org/10.1016/j.bbi.2017.02.006>
- Evans-Lacko S, Aguilar-Gaxiola S, Al-Hamzawi A, Alonso J, Benjet C, Bruffaerts R, Chiu WT, Florescu S, De Girolamo G, Gureje O, Haro JM, He Y, Hu C, Karam EG, Kawakami N, Lee S, Lund C, Kovess-Masfety V, Levinson D, Navarro-Mateu F, Pennell BE, Sampson NA, Scott KM, Tachimori H, Ten Have M, Viana MC, Williams DR, Wojtyniak BJ, Zarkov Z, Kessler RC, Chatterji S, Thornicroft G, Al-Kaisi MS, Andrade LH, Borges G, Bromet EJ, Bunting B, Caldas De Almeida JM, Cardoso G, Cia AH, Degenhardt L, Demyttenaere K, Fayyad J, Hinkov H, Hu CY, Huang Y, De Jonge P, Karam AN, Kiejna A, Lepine JP, McGrath J, Medina-Mora ME, Moskalewicz J, Piazza M, Posada-Villa J, Slade T, Stagnaro JC, Stein DJ, Torres Y, Whiteford H, Wojtyniak B (2018) Socio-economic variations in the mental health treatment gap for people with anxiety, mood, and substance use disorders: Results from the WHO World Mental Health (WMH) surveys. *Psychol Med* 48:1560–1571. <https://doi.org/10.1017/S0033291717003336>
- IHME (2020) Global Health Data Exchange (GHDx). Inst. Heal. Metrics Eval. <http://ghdx.healthdata.org/>
- Kang M, Kwon H, Park JH, Kang S, Lee Y (2020) Deep-asymmetry: asymmetry matrix image for deep learning method in pre-screening depression. *Sensors (Switzerland)* 20:1–12. <https://doi.org/10.3390/s20226526>
- Wang X, Chen S, Li T, Li W, Zhou Y, Zheng J, Chen Q, Yan J, Tang B (2020) Depression risk prediction for Chinese microblogs via deep-learning methods: content analysis. *JMIR Med Inform* 8:e17958. <https://doi.org/10.2196/17958>
- Li X, La R, Wang Y, Hu B, Zhang X (2020) A deep learning approach for mild depression recognition based on functional connectivity using electroencephalography. *Front Neurosci*. <https://doi.org/10.3389/fnins.2020.00192>
- Little B, Alshabrawy O, Stow D, Ferrier IN, McNaney R, Jackson DG, Ladha K, Ladha C, Ploetz T, Bacardit J, Olivier P, Gallagher P, O'Brien JT (2021) Deep learning-based automated speech detection as a marker of social functioning in late-life depression. *Psychol Med* 51:1441–1450. <https://doi.org/10.1017/S0033291719003994>
- Thoduparambil PP, Dominic A, Varghese SM (2020) EEG-based deep learning model for the automatic detection of clinical depression. *Phys Eng Sci Med* 43:1349–1360. <https://doi.org/10.1007/s13246-020-00938-4>
- Fan T, Hu Y, Xin J, Zhao M, Wang J (2020) Analyzing the genes and pathways related to major depressive disorder via a systems biology approach. *Brain Behav*. <https://doi.org/10.1002/brb3.1502>
- Dipnall JF, Pasco JA, Berk M, Williams LJ, Dodd S, Jacka FN, Meyer D (2016) Into the bowels of depression: unravelling medical symptoms associated with depression by applying machine-learning techniques to a community based population sample. *PLoS ONE* 11:e0167055. <https://doi.org/10.1371/journal.pone.0167055>
- Chen P, Liu Q, Wei L, Zhao B, Jia Y, Lv H, Fei X (2019) Automatically structuring on Chinese ultrasound report of cerebrovascular diseases via natural language processing. *IEEE Access* 7:89043–89050. <https://doi.org/10.1109/ACCESS.2019.2923221>
- Liu Q, Xia F, Yin Q, Jiang R (2018) Chromatin accessibility prediction via a hybrid deep convolutional neural network. *Bioinformatics* 34:732–738. <https://doi.org/10.1093/bioinformatics/btx679>
- Wei T, Li X, Stojanovic V (2021) Input-to-state stability of impulsive reaction–diffusion neural networks with infinite distributed delays. *Nonlinear Dyn* 103:1733–1755. <https://doi.org/10.1007/s11071-021-06208-6>
- Dev A, Roy N, Islam MK, Biswas C, Ahmed HU, Amin MA, Sarker F, Vaidyanathan R, Mamun KA (2022) Exploration of EEG-based depression biomarkers identification techniques and their applications: a systematic review. *IEEE*

- Access 10:16756–16781. <https://doi.org/10.1109/ACCESS.2022.3146711>
22. Abelha M, Fernandes S, Mesquita D, Seabra F, Ferreira-Oliveira AT (2020) Graduate employability and competence development in higher education—a systematic literature review using PRISMA. *Sustain* 12:5900. <https://doi.org/10.3390/SU12155900>
 23. Singh S, Kumar K (2020) Review of literature of lean construction and lean tools using systematic literature review technique (2008–2018). *Ain Shams Eng J* 11:465–471. <https://doi.org/10.1016/j.asej.2019.08.012>
 24. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hróbjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ* 372:n71. <https://doi.org/10.1136/bmj.n71>
 25. Teelhawod N, Akhtar F, Bin Heyat MB, Tripathi P, Mehrotra R, Asfaw AB, Al Shorman O, Masadeh M (2021) Machine learning in E-health: a comprehensive survey of anxiety. In: 2021 Int. Conf. Data Anal. Bus. Ind. ICDABI 2021. IEEE, pp 167–172. <https://doi.org/10.1109/ICDABI53623.2021.9655966>
 26. Akhtar F, Bin Heyat MB, Li JP, Patel PK, Rishipal, Guragai B (2020) Role of machine learning in human stress: a review. In: 2020 17th int. comput. conf. wavelet act. media technol. inf. process. ICCWAMTIP 2020, IEEE, pp 170–174. <https://doi.org/10.1109/ICWAMTIP51612.2020.9317396>
 27. Guragai B, Alshorman O, Masadeh M, Bin Heyat MB (2020) A survey on deep learning classification algorithms for motor imagery. In: Proc. Int. Conf. Microelectron. ICM, IEEE, pp 1–4. <https://doi.org/10.1109/ICM50269.2020.9331503>
 28. de Souza Filho EM, Veiga Rey HC, Frajttag RM, Arrowsmith Cook DM, de Carvalho LND, Pinho Ribeiro AL, Amaral J (2021) Can machine learning be useful as a screening tool for depression in primary care? *J Psychiatr Res* 132:1–6. <https://doi.org/10.1016/j.jpsychires.2020.09.025>
 29. Zhang Y, Wang S, Hermann A, Joly R, Pathak J (2021) Development and validation of a machine learning algorithm for predicting the risk of postpartum depression among pregnant women. *J Affect Disord* 279:1–8. <https://doi.org/10.1016/j.jad.2020.09.113>
 30. Poletti S, Vai B, Mazza MG, Zanardi R, Lorenzi C, Calesella F, Cazzetta S, Branchi I, Colombo C, Furlan R, Benedetti F (2021) A peripheral inflammatory signature discriminates bipolar from unipolar depression: a machine learning approach. *Prog Neuro-Psychopharmacol Biol Psychiatry*. <https://doi.org/10.1016/j.pnpbp.2020.110136>
 31. Pearson R, Pisner D, Meyer B, Shumake J, Beevers CG (2019) A machine learning ensemble to predict treatment outcomes following an internet intervention for depression. *Psychol Med* 49:2330–2341. <https://doi.org/10.1017/S003329171800315X>
 32. Hochman E, Feldman B, Weizman A, Krivoy A, Gur S, Barzilay E, Gabay H, Levy J, Levinkron O, Lawrence G (2021) Development and validation of a machine learning-based postpartum depression prediction model: a nationwide cohort study. *Depress Anxiety* 38:400–411. <https://doi.org/10.1002/da.23123>
 33. Liu Y, Admon R, Mellem MS, Belleau EL, Kaiser RH, Clegg R, Beltzer M, Goer F, Vitaliano G, Ahammad P, Pizzagalli DA (2020) Machine learning identifies large-scale reward-related activity modulated by dopaminergic enhancement in major depression. *Biol Psychiatry Cogn Neurosci Neuroimaging* 5:163–172. <https://doi.org/10.1016/j.bpsc.2019.10.002>
 34. Kambaitz J, Goerigk S, Gattaz W, Falkai P, Benseñor IM, Lotufo PA, Bühner M, Koutsouleris N, Padberg F, Brunoni AR (2020) Clinical patterns differentially predict response to transcranial direct current stimulation (tDCS) and escitalopram in major depression: a machine learning analysis of the ELECT-TDCS study. *J Affect Disord* 265:460–467. <https://doi.org/10.1016/j.jad.2020.01.118>
 35. Na KS, Cho SE, Geem ZW, Kim YK (2020) Predicting future onset of depression among community dwelling adults in the Republic of Korea using a machine learning algorithm. *Neurosci Lett*. <https://doi.org/10.1016/j.neulet.2020.134804>
 36. Helbich M, Yao Y, Liu Y, Zhang J, Liu P, Wang R (2019) Using deep learning to examine street view green and blue spaces and their associations with geriatric depression in Beijing, China. *Environ Int* 126:107–117. <https://doi.org/10.1016/j.envint.2019.02.013>
 37. Oh J, Yun K, Mao U, Kim TS, Chae JH (2019) Identifying depression in the National Health and Nutrition Examination Survey data using a deep learning algorithm. *J Affect Disord* 257:623–631. <https://doi.org/10.1016/j.jad.2019.06.034>
 38. Mumtaz W, Qayyum A (2019) A deep learning framework for automatic diagnosis of unipolar depression. *Int J Med Inform*. <https://doi.org/10.1016/j.ijmedinf.2019.103983>
 39. Gui R, Chen T, Nie H (2019) The impact of emotional music on active ROI in patients with depression based on deep learning: a task-state fMRI study. *Comput Intell Neurosci*. <https://doi.org/10.1155/2019/5850830>
 40. Schultebrucks K, Yadav V, Shalev AY, Bonanno GA, Galatzer-Levy IR (2022) Deep learning-based classification of posttraumatic stress disorder and depression following trauma utilizing visual and auditory markers of arousal and mood. *Psychol Med* 52:957–967. <https://doi.org/10.1017/S0033291720002718>
 41. Zhang B, Wang W, Wang S, Li S, Liu M, Wang L, Yang C (2021) Clinical study on electronic medical neuroelectric stimulation based on the internet of things to treat epilepsy patients with anxiety and depression. *J Healthc Eng*. <https://doi.org/10.1155/2021/6667309>
 42. Qayyum S, Sultana A, Bin Heyat MB, Rahman K, Akhtar F, Ul Haq A, Alkhamis BA, Alqahtani MA, Gahtani RM (2023) Therapeutic efficacy of a formulation prepared with *Linum usitatissimum* L., *Plantago ovata* Forssk., and honey on uncomplicated pelvic inflammatory disease analyzed with machine learning techniques. *Pharmaceutics* 15:643. <https://doi.org/10.3390/pharmaceutics15020643>
 43. Ali L, He Z, Cao W, Rauf HT, Imrana Y, Bin Heyat MB (2021) MMDD-ensemble: a multimodal data-driven ensemble approach for Parkinson's disease detection. *Front Neurosci* 15:1–11. <https://doi.org/10.3389/fnins.2021.754058>
 44. Iqbal MS, Abbasi R, Bin Heyat MB, Akhtar F, Abdelgelil AS, Albogami S, Fayad E, Iqbal MA (2022) Recognition of mRNA N4 acetylcytidine (ac4C) by using non-deep vs. deep learning. *Appl Sci* 12:1–16. <https://doi.org/10.3390/app12031344>
 45. Bin Heyat MB, Akhtar F, Khan A, Noor A, Benjdira B, Qamar Y, Abbas SJ, Lai D (2020) A novel hybrid machine learning classification for the detection of bruxism patients using physiological signals. *Appl Sci* 10:1–16. <https://doi.org/10.3390/app10217410>
 46. Bin Heyat MB, Akhtar F, Abbas SJ, Al-Sarem M, Alqarafi A, Stalin A, Abbasi R, Muaad AY, Lai D, Wu K (2022) Wearable flexible electronics based cardiac electrode for researcher mental stress detection system using machine learning models on single lead electrocardiogram signal. *Biosensors* 12:427. <https://doi.org/10.3390/bios12060427>
 47. Pal R, Adhikari D, Bin Heyat MB, Ullah I, You Z (2023) Yoga meets intelligent internet of things: recent challenges and future directions. *Bioengineering* 10:459. <https://doi.org/10.3390/bioengineering10040459>
 48. Bin Heyat MB, Akhtar F, Sultana A, Tumrani S, Teelhawod BN, Abbasi R, Amjad Kamal M, Muaad AY, Lai D, Wu K (2022) Role of oxidative stress and inflammation in insomnia sleep

- disorder and cardiovascular diseases: herbal antioxidants and anti-inflammatory coupled with insomnia detection using machine learning. *Curr Pharm Des* 28:3618–3636. <https://doi.org/10.2174/1381612829666221201161636>
49. Sultana A, Rahman K, Bin Heyat MB, Akhtar F, Muaad AY (2022) Role of inflammation, oxidative stress, and mitochondrial changes in premenstrual psychosomatic behavioral symptoms with anti-inflammatory, antioxidant herbs, and nutritional supplements. *Oxid Med Cell Longev* 2022:3599246. <https://doi.org/10.1155/2022/3599246>
 50. Sultana A, Begum W, Saeedi R, Rahman K, Bin Heyat MB, Akhtar F, Son NT, Ullah H (2022) Experimental and computational approaches for the classification and correlation of temperament (Mizaj) and uterine dystemperament (Su’-I-Mizaj Al-Rahim) in abnormal vaginal discharge (Sayalan Al-Rahim) based on clinical analysis using support vector mach. *Complexity* 2022:1–16. <https://doi.org/10.1155/2022/5718501>
 51. Koutsouleris N, Dwyer DB, Degenhardt F, Maj C, Urquijo-Castro MF, Sanfelici R, Popovic D, Oeztuerk O, Haas SS, Weiske J, Ruef A, Kambeitz-Illankovic L, Antonucci LA, Neufang S, Schmidt-Kraepelin C, Ruhrmann S, Penzel N, Kambeitz J, Haidl TK, Rosen M, Chisholm K, Riecher-Rössler A, Egloff L, Schmidt A, Andreou C, Hietala J, Schirmer T, Romer G, Walger P, Franscini M, Traber-Walker N, Schimmelmann BG, Flückiger R, Michel C, Rössler W, Borisov O, Krawitz PM, Heekeren K, Buechler R, Pantelis C, Falkai P, Salokangas RKR, Lencer R, Bertolino A, Borgwardt S, Noethen M, Brambilla P, Wood SJ, Upthegrove R, Schultze-Lutter F, Theodoridou A, Meisenzahl E (2021) Multimodal machine learning workflows for prediction of psychosis in patients with clinical high-risk syndromes and recent-onset depression. *JAMA Psychiat* 78:195–209. <https://doi.org/10.1001/jamapsychiatry.2020.3604>
 52. Byeon H (2020) Development of a depression in Parkinson’s disease prediction model using machine learning. *World J Psychiatry* 10:234–244. <https://doi.org/10.5498/wjp.v10.i10.234>
 53. Richter T, Fishbain B, Markus A, Richter-Levin G, Okon-Singer H (2020) Using machine learning-based analysis for behavioral differentiation between anxiety and depression. *Sci Rep*. <https://doi.org/10.1038/s41598-020-72289-9>
 54. van Bronswijk SC, Bruijninks SJE, Lorenzo-Luaces L, Derubeis RJ, Lemmens LHJM, Peeters FPML, Huibers MJH (2021) Cross-trial prediction in psychotherapy: external validation of the personalized advantage index using machine learning in two Dutch randomized trials comparing CBT versus IPT for depression. *Psychother Res* 31:78–91. <https://doi.org/10.1080/10503307.2020.1823029>
 55. Shin D, Lee KJ, Adeluwa T, Hur J (2020) Machine learning-based predictive modeling of postpartum depression. *J Clin Med* 9:1–14. <https://doi.org/10.3390/jcm9092899>
 56. Németh R, Sik D, Máté F (2020) Machine learning of concepts hard even for humans: the case of online depression forums. *Int J Qual Methods*. <https://doi.org/10.1177/1609406920949338>
 57. Benfares C, Akhrif O, El Idrissi YEB, Hamid K (2021) A clinical support system for classification and prediction of depression using machine learning methods. *Comput Intell* 37:1619–1632. <https://doi.org/10.1111/coin.12377>
 58. Qi B, Fiori LM, Turecki G, Trakadis YJ (2020) Machine learning analysis of blood microRNA data in major depression: a case-control study for biomarker discovery. *Int J Neuropsychopharmacol* 23:505–510. <https://doi.org/10.1093/ijnp/pyaa029>
 59. Alsagri HS, Ykhlef M (2020) Machine learning-based approach for depression detection in twitter using content and activity features. *IEICE Trans Inf Syst E* 103D:1825–1832. <https://doi.org/10.1587/transinf.2020EDP7023>
 60. Solomonov N, Lee J, Banerjee S, Flückiger C, Kanellopoulos D, Gunning FM, Sirey JA, Liston C, Raue PJ, Hull TD, Areán PA, Alexopoulos GS (2021) Modifiable predictors of nonresponse to psychotherapies for late-life depression with executive dysfunction: a machine learning approach. *Mol Psychiatry* 26:5190–5198. <https://doi.org/10.1038/s41380-020-0836-z>
 61. Tennenhouse LG, Marrie RA, Bernstein CN, Lix LM (2020) Machine-learning models for depression and anxiety in individuals with immune-mediated inflammatory disease. *J Psychosom Res*. <https://doi.org/10.1016/j.jpsychores.2020.110126>
 62. Rajpurkar P, Yang J, Dass N, Vale V, Keller AS, Irvin J, Taylor Z, Basu S, Ng A, Williams LM (2020) Evaluation of a machine learning model based on pretreatment symptoms and electroencephalographic features to predict outcomes of antidepressant treatment in adults with depression: a prespecified secondary analysis of a randomized clinical trial. *JAMA Netw Open*. <https://doi.org/10.1001/jamanetworkopen.2020.6653>
 63. Shatte ABR, Hutchinson DM, Fuller-Tyszkiewicz M, Teague SJ (2020) Social media markers to identify fathers at risk of postpartum depression: a machine learning approach. *Cyberpsychol Behav Soc Netw* 23:611–618. <https://doi.org/10.1089/cyber.2019.0746>
 64. Helbich M, Hagenauer J, Roberts H (2020) Relative importance of perceived physical and social neighborhood characteristics for depression: a machine learning approach. *Soc Psychiatry Psychiatr Epidemiol* 55:599–610. <https://doi.org/10.1007/s00127-019-01808-5>
 65. Razavi R, Gharipour A, Gharipour M (2020) Depression screening using mobile phone usage metadata: a machine learning approach. *J Am Med Inform Assoc* 27:522–530. <https://doi.org/10.1093/jamia/ocz221>
 66. Zhang W, Liu H, Silenzio VMB, Qiu P, Gong W (2020) Machine learning models for the prediction of postpartum depression: application and comparison based on a cohort study. *JMIR Med Inform*. <https://doi.org/10.2196/15516>
 67. Yang Z, Chen C, Li H, Yao L, Zhao X (2020) Unsupervised classifications of depression levels based on machine learning algorithms perform well as compared to traditional norm-based classifications. *Front Psychiatry*. <https://doi.org/10.3389/fpsy.2020.00045>
 68. Zhdanov A, Atluri S, Wong W, Vaghei Y, Daskalakis ZJ, Blumberg DM, Frey BN, Giacobbe P, Lam RW, Milev R, Mueller DJ, Turecki G, Parikh SV, Rotzinger S, Soares CN, Brenner CA, Vila-Rodriguez F, McAndrews MP, Kleffner K, Alonso-Prieto E, Arnott SR, Foster JA, Strother SC, Uher R, Kennedy SH, Farzan F (2020) Use of machine learning for predicting escitalopram treatment outcome from electroencephalography recordings in adult patients with depression. *JAMA Netw Open* 3:e1918377. <https://doi.org/10.1001/jamanetworkopen.2019.18377>
 69. Zhao M, Feng Z (2020) Machine learning methods to evaluate the depression status of Chinese recruits: a diagnostic study. *Neuropsychiatr Dis Treat* 16:2743–2752. <https://doi.org/10.2147/NDT.S275620>
 70. Aguilera A, Figueroa CA, Hernandez-Ramos R, Sarkar U, Cemballi A, Gomez-Pathak L, Miramontes J, Yom-Tov E, Chakraborty B, Yan X, Xu J, Modiri A, Aggarwal J, Jay Williams J, Lyles CR (2020) MHealth app using machine learning to increase physical activity in diabetes and depression: clinical trial protocol for the DIAMANTE Study. *BMJ Open*. <https://doi.org/10.1136/bmjopen-2019-034723>
 71. Delgado J, Salas Duhne PG (2020) Targeted prescription of cognitive-behavioral therapy versus person-centered counseling for depression using a machine learning approach. *J Consult Clin Psychol* 88:14–24. <https://doi.org/10.1037/ccp0000476>
 72. Cui L, Wang C, Wu Z, Peng D, Huang J, Zhang C, Huang J, Hong W, Wang Y, Chen J, Liu T, Rong H, Yang H, Fang Y (2020) Symptomatology differences of major depression in psychiatric

- versus general hospitals: a machine learning approach. *J Affect Disord* 260:349–360. <https://doi.org/10.1016/j.jad.2019.09.030>
73. Wollenhaupt-Aguiar B, Librenza-Garcia D, Bristot G, Przybylski L, Stertz L, Kubiachi Burque R, Ceresér KM, Spanemberg L, Caldieraro MA, Frey BN, Fleck MP, Kauer-Sant'Anna M, Cavalcante Passos I, Kapczinski F (2020) Differential biomarker signatures in unipolar and bipolar depression: a machine learning approach. *Aust N Z J Psychiatry* 54:393–401. <https://doi.org/10.1177/0004867419888027>
 74. McGinnis EW, Anderau SP, Hruschak J, Gurchiek RD, Lopez-Duran NL, Fitzgerald K, Rosenblum KL, Muzik M, McGinnis RS (2019) Giving voice to vulnerable children: machine learning analysis of speech detects anxiety and depression in early childhood. *IEEE J Biomed Health Inform* 23:2294–2301. <https://doi.org/10.1109/JBHI.2019.2913590>
 75. Kim H, Lee SH, Lee SE, Hong S, Kang HJ, Kim N (2019) Depression prediction by using ecological momentary assessment, actiwatch data, and machine learning: observational study on older adults living alone. *JMIR MHealth UHealth*. <https://doi.org/10.2196/14149>
 76. Gong J, Simon GE, Liu S (2019) Machine learning discovery of longitudinal patterns of depression and suicidal ideation. *PLoS ONE*. <https://doi.org/10.1371/journal.pone.0222665>
 77. Besteher B, Gaser C, Nenadić I (2019) Machine-learning based brain age estimation in major depression showing no evidence of accelerated aging. *Psychiatry Res Neuroimaging* 290:1–4. <https://doi.org/10.1016/j.pscychres.2019.06.001>
 78. Li X, Zhang X, Zhu J, Mao W, Sun S, Wang Z, Xia C, Hu B (2019) Depression recognition using machine learning methods with different feature generation strategies. *Artif Intell Med*. <https://doi.org/10.1016/j.artmed.2019.07.004>
 79. Fatima I, Abbasi BUD, Khan S, Al-Saeed M, Ahmad HF, Mumtaz R (2019) Prediction of postpartum depression using machine learning techniques from social media text. *Expert Syst*. <https://doi.org/10.1111/exsy.12409>
 80. Kasthurirathne SN, Biondich PG, Grannis SJ, Purkayastha S, Vest JR, Jones JF (2019) Identification of patients in need of advanced care for depression using data extracted from a statewide health information exchange: a machine learning approach. *J Med Internet Res*. <https://doi.org/10.2196/13809>
 81. Zandvakili A, Philip NS, Jones SR, Tyrka AR, Greenberg BD, Carpenter LL (2019) Use of machine learning in predicting clinical response to transcranial magnetic stimulation in comorbid posttraumatic stress disorder and major depression: a resting state electroencephalography study. *J Affect Disord* 252:47–54. <https://doi.org/10.1016/j.jad.2019.03.077>
 82. Zhao K, So HC (2019) Drug repositioning for schizophrenia and depression/anxiety disorders: a machine learning approach leveraging expression data. *IEEE J Biomed Health Inform* 23:1304–1315. <https://doi.org/10.1109/JBHI.2018.2856535>
 83. Dinga R, Marquand AF, Veltman DJ, Beekman ATF, Schoevers RA, van Hemert AM, Penninx BWJH, Schmaal L (2018) Predicting the naturalistic course of depression from a wide range of clinical, psychological, and biological data: a machine learning approach. *Transl Psychiatry*. <https://doi.org/10.1038/s41398-018-0289-1>
 84. Wallert J, Gustafson E, Held C, Madison G, Norlund F, Von Essen L, Olsson EMG (2018) Predicting adherence to internet-Delivered psychotherapy for symptoms of depression and anxiety after myocardial infarction: machine learning insights from the U-CARE heart randomized controlled trial. *J Med Internet Res*. <https://doi.org/10.2196/10754>
 85. Zilcha-Mano S, Roose SP, Brown PJ, Rutherford BR (2018) A machine learning approach to identifying placebo responders in late-life depression trials. *Am J Geriatr Psychiatry* 26:669–677. <https://doi.org/10.1016/j.jagp.2018.01.001>
 86. Kautzky A, Dold M, Bartova L, Spies M, Vanicek T, Souery D, Montgomery S, Mendlewicz J, Zohar J, Fabbri C, Serretti A, Lanzenberger R, Kasper S (2018) Refining prediction in treatment-resistant depression: results of machine learning analyses in the TRD III sample. *J Clin Psychiatry*. <https://doi.org/10.4088/JCP.16m11385>
 87. Hilbert K, Lueken U, Muehlhan M, Beesdo-Baum K (2017) Separating generalized anxiety disorder from major depression using clinical, hormonal, and structural MRI data: a multimodal machine learning study. *Brain Behav*. <https://doi.org/10.1002/brb3.633>
 88. Dipnall JF, Pasco JA, Berk M, Williams LJ, Dodd S, Jacka FN, Meyer D (2017) Why so GLUMM? Detecting depression clusters through graphing lifestyle-environs using machine-learning methods (GLUMM). *Eur Psychiatry* 39:40–50. <https://doi.org/10.1016/j.eurpsy.2016.06.003>
 89. Cvetković J (2017) Breast cancer patients' depression prediction by machine learning approach. *Cancer Invest* 35:569–572. <https://doi.org/10.1080/07357907.2017.1363892>
 90. Mehlretter J, Rollins C, Benrimoh D, Fratila R, Perlman K, Israel S, Miresco M, Wakid M, Turecki G (2020) Analysis of features selected by a deep learning model for differential treatment selection in depression. *Front Artif Intell*. <https://doi.org/10.3389/frai.2019.00031>
 91. Lin E, Kuo PH, Liu YL, Yu YWY, Yang AC, Tsai SJ (2018) A deep learning approach for predicting antidepressant response in major depression using clinical and genetic biomarkers. *Front Psychiatry*. <https://doi.org/10.3389/fpsy.2018.00290>
 92. Jawad K, Mahto R, Das A, Ahmed SU, Aziz RM, Kumar P (2023) Novel cuckoo search-based metaheuristic approach for deep learning prediction of depression. *Appl Sci* 13:5322. <https://doi.org/10.3390/app13095322>
 93. Black CN, Bot M, Scheffer PG, Cuijpers P, Penninx BWJH (2015) Is depression associated with increased oxidative stress? A systematic review and meta-analysis. *Psychoneuroendocrinology* 51:164–175. <https://doi.org/10.1016/j.psyneuen.2014.09.025>
 94. Uliaszek AA, Zinbarg RE, Mineka S, Craske MG, Sutton JM, Griffith JW, Rose R, Waters A, Hammen C (2010) The role of neuroticism and extraversion in the stress-anxiety and stress-depression relationships. *Anxiety Stress Coping* 23:363–381. <https://doi.org/10.1080/10615800903377264>
 95. Basavanthappa B (2011) Essentials of mental health nursing. <https://doi.org/10.5005/jp/books/11321>
 96. Jacobson NS, Dobson KS, Truax PA, Addis ME, Koerner K, Gollan JK, Gortner E, Prince SE (1996) A component analysis of cognitive—behavioral treatment for depression. *J Consult Clin Psychol* 64:295–304. <https://doi.org/10.1037/0022-006X.64.2.295>
 97. Salustri C, Squitti R, Zappasodi F, Ventriglia M, Bevacqua MG, Fontana M, Tecchio F (2010) Oxidative stress and brain glutamate-mediated excitability in depressed patients. *J Affect Disord* 127:321–325. <https://doi.org/10.1016/j.jad.2010.05.012>
 98. Cho Y, Lee JK, Kim DH, Park JH, Choi M, Kim HJ, Nam MJ, Lee KU, Han K, Park YG (2019) Factors associated with quality of life in patients with depression: a nationwide population-based study. *PLoS ONE* 14:e0219455. <https://doi.org/10.1371/journal.pone.0219455>
 99. Yang L, Zhao Y, Wang Y, Liu L, Zhang X, Li B, Cui R (2015) The effects of psychological stress on depression. *Curr Neuropharmacol* 13:494–504. <https://doi.org/10.2174/1570159x1304150831150507>
 100. Wirtz PH, von Känel R (2017) Psychological stress, inflammation, and coronary heart disease. *Curr Cardiol Rep* 19:111. <https://doi.org/10.1007/s11886-017-0919-x>

101. Hamon M, Blier P (2013) Monoamine neurocircuitry in depression and strategies for new treatments. *Prog Neuro-Psychopharmacol Biol Psychiatry* 45:54–63. <https://doi.org/10.1016/j.pnpbp.2013.04.009>
102. Maletic V, Eramo A, Gwin K, Offord SJ, Duffy RA (2017) The role of norepinephrine and its α -adrenergic receptors in the pathophysiology and treatment of major depressive disorder and schizophrenia: a systematic review. *Front Psychiatry*. <https://doi.org/10.3389/fpsy.2017.00042>
103. Gold PW, Wong ML (2021) Re-assessing the catecholamine hypothesis of depression: the case of melancholic depression. *Mol Psychiatry* 26:6121–6124. <https://doi.org/10.1038/s41380-021-01133-x>
104. Peacock BN, Scheiderer DJ, Kellermann GH (2017) Biomolecular aspects of depression: a retrospective analysis. *Compr Psychiatry* 73:168–180. <https://doi.org/10.1016/j.comppsych.2016.11.002>
105. Hernández-Hernández OT, Martínez-Mota L, Herrera-Pérez JJ, Jiménez-Rubio G (2018) Role of estradiol in the expression of genes involved in serotonin neurotransmission: implications for female depression. *Curr Neuropharmacol* 17:459–471. <https://doi.org/10.2174/1570159x16666180628165107>
106. Labonté B, Engmann O, Purushothaman I, Menard C, Wang J, Tan C, Scarpa JR, Moy G, Loh YHE, Cahill M, Lorsch ZS, Hamilton PJ, Calipari ES, Hodes GE, Issler O, Kronman H, Pfau M, Obradovic ALJ, Dong Y, Neve RL, Russo S, Kazarskis A, Tamminga C, Mechawar N, Turecki G, Zhang B, Shen L, Nestler EJ (2017) Sex-specific transcriptional signatures in human depression. *Nat Med* 23:1102–1111. <https://doi.org/10.1038/nm.4386>
107. Weng TT, Hao JH, Qian QW, Cao H, Fu JL, Sun Y, Huang L, Tao FB (2012) Is there any relationship between dietary patterns and depression and anxiety in Chinese adolescents? *Public Health Nutr* 15:673–682. <https://doi.org/10.1017/S1368980011003077>
108. Finger BC, Dinan TG, Cryan JF (2011) High-fat diet selectively protects against the effects of chronic social stress in the mouse. *Neuroscience* 192:351–360. <https://doi.org/10.1016/j.neuroscience.2011.06.072>
109. Werner A (2004) Psychodynamic treatment of depression. *Am J Psychiatry* 161:2146–2146. <https://doi.org/10.1176/appi.ajp.161.11.2146>
110. Kim KH (2021) Level of troponin release can aid in early exclusion of stress-induced (Takotsubo) cardiomyopathy. *J Cardiovasc Imaging* 29:234–235. <https://doi.org/10.4250/jcvi.2021.0076>
111. Mohr DC, Tomasino KN, Lattie EG, Palac HL, Kwasny MJ, Weingard K, Karr CJ, Kaiser SM, Rossom RC, Bardsley LR, Caccamo L, Stiles-Shields C, Schueller SM (2017) Intellicare: an eclectic, skills-based app suite for the treatment of depression and anxiety. *J Med Internet Res*. <https://doi.org/10.2196/jmir.6645>
112. Robinson SD, Lee TW, Christie DL, Birch NP (2015) Tissue plasminogen activator inhibits NMDA-receptor-mediated increases in calcium levels in cultured hippocampal neurons. *Front Cell Neurosci*. <https://doi.org/10.3389/fncel.2015.00404>
113. Cowen PJ (2010) Not fade away: the HPA axis and depression. *Psychol Med* 40:1–4. <https://doi.org/10.1017/S0033291709005558>
114. Wallace CJK, Foster JA, Soares CN, Milev RV (2020) The effects of probiotics on symptoms of depression: protocol for a double-blind randomized placebo-controlled trial. *Neuropsychobiology* 79:108–116. <https://doi.org/10.1159/000496406>
115. McEwen BS (1999) Stress and hippocampal plasticity. *Annu Rev Neurosci* 22:105–122. <https://doi.org/10.1146/annurev.neuro.22.1.105>
116. Bremner JD, Narayan M, Anderson ER, Staib LH, Miller HL, Charney DS (2000) Hippocampal volume reduction in major depression. *Am J Psychiatry* 157:115–117. <https://doi.org/10.1176/ajp.157.1.115>
117. Bitsko RH, Holbrook JR, Ghandour RM, Blumberg SJ, Visser SN, Perou R, Walkup JT (2018) Epidemiology and impact of health care provider-diagnosed anxiety and depression among US children. *J Dev Behav Pediatr* 39:395–403. <https://doi.org/10.1097/DBP.0000000000000571>
118. Schmidt PJ (2005) Depression, the perimenopause, and estrogen therap. *Ann N Y Acad Sci*. <https://doi.org/10.1196/annals.1347.003>
119. Sramek JJ, Cutler NR (2011) The impact of gender on antidepressants. *Curr Top Behav Neurosci* 8:231–249. https://doi.org/10.1007/7854_2010_118
120. Emeny RT, Bidlingmaier M, Lacruz ME, Linkohr B, Peters A, Reincke M, Ladwig KH (2014) Mind over hormones: sex differences in associations of well-being with IGF-I, IGFBP-3 and physical activity in the KORA-Age study. *Exp Gerontol* 59:58–64. <https://doi.org/10.1016/j.exger.2014.08.001>
121. Thase ME, Trivedi MH, Rush AJ (1995) MAOIs in the contemporary treatment of depression. *Neuropsychopharmacology* 12:185–219. [https://doi.org/10.1016/0893-133X\(94\)00058-8](https://doi.org/10.1016/0893-133X(94)00058-8)
122. Penninx BWJH, Geerlings SW, Deeg DJH, Van Eijk JTM, Van Tilburg W, Beekman ATF (1999) Minor and major depression and the risk of death in older persons. *Arch Gen Psychiatry* 56:889–895. <https://doi.org/10.1001/archpsyc.56.10.889>
123. Ramaker RC, Bowling KM, Lasseigne BN, Hagenauer MH, Hardigan AA, Davis NS, Gertz J, Cartagena PM, Walsh DM, Vawter MP, Schatzberg AF, Barchas JD, Watson SJ, Bunney BG, Akil H, Bunney WE, Li JZ, Cooper SJ, Myers RM (2017) Post-mortem molecular profiling of three psychiatric disorders. *Genome Med* 9:72. <https://doi.org/10.1186/s13073-017-0458-5>
124. Abraham J, Mudd JO, Kapur N, Klein K, Champion HC, Wittstein IS (2009) Stress cardiomyopathy after intravenous administration of catecholamines and beta-receptor agonists. *J Am Coll Cardiol* 53:1320–1325. <https://doi.org/10.1016/j.jacc.2009.02.020>
125. Stefanatou A, Kouris N, Lekakis J (2010) Treatment of depression in elderly patients with cardiovascular disease: research data and future prospects. *Hellenic J Cardiol* 51:142–152
126. Morava E, Gardeitchik T, Kozicz T, de Boer L, Koene S, de Vries MC, McFarland R, Roobol T, Rodenburg RJT, Verhaak CM (2010) Depressive behaviour in children diagnosed with a mitochondrial disorder. *Mitochondrion* 10:528–533. <https://doi.org/10.1016/j.mito.2010.05.011>
127. Gardner A, Johansson A, Wibom R, Nennesmo I, Von Döbeln U, Hagenfeldt L, Hällström T (2003) Alterations of mitochondrial function and correlations with personality traits in selected major depressive disorder patients. *J Affect Disord* 76:55–68. [https://doi.org/10.1016/S0165-0327\(02\)00067-8](https://doi.org/10.1016/S0165-0327(02)00067-8)
128. Bansal Y, Kuhad A (2016) Mitochondrial Dysfunction in Depression. *Curr Neuropharmacol* 14:610–618. <https://doi.org/10.2174/1570159x14666160229114755>
129. Zhang D, Wen X, Wang X, Shi M, Zhao Y (2009) Antidepressant effect of Shudihuang on mice exposed to unpredictable chronic mild stress. *J Ethnopharmacol* 123:55–60. <https://doi.org/10.1016/j.jep.2009.02.029>
130. Bagdy G, Juhasz G, Gonda X (2012) A depresszió új, bizonyítékokon alapuló gén-környezet interakciós modellje. *Neuropsychopharmacol Hungarica* 14:213–220. <https://doi.org/10.5706/nph201212001>
131. Pawlak R, Rao BSS, Melchor JP, Chattarji S, McEwen B, Strickland S (2005) Tissue plasminogen activator and plasminogen mediate stress-induced decline of neuronal and cognitive functions in the mouse hippocampus. *Proc Natl Acad Sci USA* 102:18201–18206. <https://doi.org/10.1073/pnas.0509232102>
132. Ryder AL, Cohen BE (2021) Evidence for depression and anxiety as risk factors for heart disease and stroke: implications for primary care. *Fam Pract* 38:365–367. <https://doi.org/10.1093/fampra/cmab031>

133. Dunn AL, Trivedi MH, Kampert JB, Clark CG, Chambliss HO (2005) Exercise treatment for depression: efficacy and dose response. *Am J Prev Med* 28:1–8. <https://doi.org/10.1016/j.amepre.2004.09.003>
134. Maes M (2001) Psychological stress and the inflammatory response system. *Clin Sci* 101:193–194. <https://doi.org/10.1042/CS20010157>
135. Cuijpers P, Quero S, Dowrick C, Arroll B (2019) Psychological treatment of depression in primary care: recent developments. *Curr Psychiatry Rep* 21:129. <https://doi.org/10.1007/s11920-019-1117-x>
136. Schuch FB, Vancampfort D, Richards J, Rosenbaum S, Ward PB, Stubbs B (2016) Exercise as a treatment for depression: a meta-analysis adjusting for publication bias. *J Psychiatr Res* 77:42–51. <https://doi.org/10.1016/j.jpsychires.2016.02.023>
137. Kiecolt-Glaser JK, Belury MA, Andridge R, Malarkey WB, Glaser R (2011) Omega-3 supplementation lowers inflammation and anxiety in medical students: a randomized controlled trial. *Brain Behav Immun* 25:1725–1734. <https://doi.org/10.1016/j.bbi.2011.07.229>
138. Hill MF, Singal PK (1996) Antioxidant and oxidative stress changes during heart failure subsequent to myocardial infarction in rats. *Am J Pathol* 148:291–300
139. Cheng S, Zhu Z, Li H, Wang W, Jiang Z, Pan F, Liu D, Ho RCM, Ho CSH (2023) Rifaximin ameliorates depression-like behaviour in chronic unpredictable mild stress rats by regulating intestinal microbiota and hippocampal tryptophan metabolism. *J Affect Disord*. <https://doi.org/10.1016/j.jad.2023.02.086>
140. O'Neill M (2001) Role of 5-HT_{1A} and 5-HT_{1B} receptors in the mediation of behavior in the forced swim test in mice. *Neuropsychopharmacology* 24:391–398. [https://doi.org/10.1016/S0893-133X\(00\)00196-2](https://doi.org/10.1016/S0893-133X(00)00196-2)
141. Giannakakis A, Zhang J, Jenjaroenpun P, Nama S, Zainolabidin N, Aau MY, Yarmishyn AA, Vaz C, Ivshina AV, Grinchuk OV, Voorhoeve M, Vardy LA, Sampath P, Kuznetsov VA, Kurochkin IV, Guccione E (2015) Contrasting expression patterns of coding and noncoding parts of the human genome upon oxidative stress. *Sci Rep*. <https://doi.org/10.1038/srep09737>
142. John S (2020) Hormones and depression in women. *Insights Depress Anxiety* 4:064–065. <https://doi.org/10.29328/journal.ida.1001022>
143. Kvam S, Kleppe CL, Nordhus IH, Hovland A (2016) Exercise as a treatment for depression: a meta-analysis. *J Affect Disord* 202:67–86. <https://doi.org/10.1016/j.jad.2016.03.063>
144. Danner M, Kasl SV, Abramson JL, Vaccarino V (2003) Association between depression and elevated C-reactive protein. *Psychosom Med* 65:347–356. <https://doi.org/10.1097/01.PSY.0000041542.29808.01>
145. Wu PL, Lee M, Huang TT (2017) Effectiveness of physical activity on patients with depression and Parkinson's disease: a systematic review. *PLoS ONE* 12:1–14. <https://doi.org/10.1371/journal.pone.0181515>
146. Imboden C, Gerber M, Beck J, Eckert A, Pühse U, Holsboer-Trachsler E, Hatzinger M (2019) Effects of aerobic exercise as add-on treatment for inpatients with moderate to severe depression on depression severity, sleep, cognition, psychological well-being, and biomarkers: study protocol, description of study population, and manipulation check. *Front Psychiatry*. <https://doi.org/10.3389/fpsy.2019.00262>
147. Mao X, Terpolilli NA, Wehn A, Cheng S, Hellal F, Liu B, Seker B, Plesnila N (2020) Progressive histopathological damage occurring up to one year after experimental traumatic brain injury is associated with cognitive decline and depression-like behavior. *J Neurotrauma* 37:1331–1341. <https://doi.org/10.1089/neu.2019.6510>
148. Amr SS, Tbakhi A (2007) Ibn Sina (Avicenna): the prince of physicians. *Ann Saudi Med* 27:134–135. <https://doi.org/10.5144/0256-4947.2007.134>
149. Suomalainen K (2018) *Sinä*, konteksti ja monitulkintaisuus. Viritäjä. <https://doi.org/10.23982/vir.63686>
150. Kökcü A (2019) İbn Sina ve İhvan-ı Safa Bağlamında Matematik-ten Metafizik Sayı ve Nicelik Algısı. *Beytulhikme Int J Philos* 9:59–74. <https://doi.org/10.18491/beytulhikme.1438>
151. Johnson D, Letchumanan V, Thum CC, Thurairajasingam S, Lee L-H (2023) A microbial-based approach to mental health: the potential of probiotics in the treatment of depression. *Nutrients*. <https://doi.org/10.3390/nu15061382>
152. Derakhshan AR (2017) Natural treatments for fissure in Ano used by traditional persian scholars, Razi (Rhazes) and Ibn Sina (Avicenna). *J Evid Based Complement Altern Med* 22:324–333. <https://doi.org/10.1177/2156587216650302>
153. I. translation by K.G. Sina (2010) *Al Qanoon fit Tibb, Idarae Kitabus Shifa*, New Dilhi
154. Anwar N, Ahmed NZ, Shahida T, Kabiruddin K, Aslam H (2017) The role of Mufarrehat (Exhilarants) in the management of depression: an evidence based approach. *J Psychiatry*. <https://doi.org/10.4172/2378-5756.1000420>
155. Khambaty M, Parikh RM (2017) Cultural aspects of anxiety disorders in India. *Dialogues Clin Neurosci* 19:117–126. <https://doi.org/10.31887/dens.2017.19.2/parikh>
156. Ahmed NZ, Alam A, Khalid M, Sheeraz M, Qamri MA (2015) An insight on Malankholia (Melancholia): Unani perspective. *Med J Islam World Acad Sci* 23:140–146. <https://doi.org/10.5505/ias.2015.58076>
157. Sarris J, Panossian A, Schweitzer I, Stough C, Scholey A (2011) Herbal medicine for depression, anxiety and insomnia: a review of psychopharmacology and clinical evidence. *Eur Neuropsychopharmacol* 21:841–860. <https://doi.org/10.1016/j.euroneuro.2011.04.002>
158. Yeung AWK, Georgieva MG, Atanasov AG, Tzvetkov NT (2019) Monoamine oxidases (MAOs) as privileged molecular targets in neuroscience: research literature analysis. *Front Mol Neurosci*. <https://doi.org/10.3389/fnmol.2019.00143>
159. Naoi M, Shamoto-Nagai M, Maruyama W (2019) Neuroprotection of multifunctional phytochemicals as novel therapeutic strategy for neurodegenerative disorders: antiapoptotic and anti-amyloidogenic activities by modulation of cellular signal pathways. *Future Neurol* 14:FNL9. <https://doi.org/10.2217/fnl-2018-0028>
160. Sofiane G, Wafa N, Ouarda D (2015) Antioxidant, antimicrobial and anti-inflammatory activities of flavonoids and tannins extracted from *Polypodium vulgare* L. *Asian J Biochem Pharm Res* 5:114–122
161. Allen J, Romay-Tallon R, Brymer KJ, Caruncho HJ, Kalynchuk LE (2018) Mitochondria and mood: mitochondrial dysfunction as a key player in the manifestation of depression. *Front Neurosci* 12:1–13. <https://doi.org/10.3389/fnins.2018.00386>
162. Khan AW, Khan AU, Shah SMM, Ullah A, Faheem M, Saleem M (2019) An updated list of neuromedicinal plants of Pakistan, their uses, and phytochemistry. *Evid Based Complement Altern Med* 2019:1–27. <https://doi.org/10.1155/2019/6191505>
163. Yeung KS, Hernandez M, Mao JJ, Haviland I, Gubili J (2018) Herbal medicine for depression and anxiety: a systematic review with assessment of potential psycho-oncologic relevance. *Phyther Res* 32:865–891. <https://doi.org/10.1002/ptr.6033>
164. Wang S, Zhang J, Zhang Z, Gao W, Yan Y, Li X, Liu C (2014) Identification of chemical constituents in the extract and rat serum from *Ziziphus jujuba* mill. by HPLC-PDA-ESI-MSn. *Iran J Pharm Res* 13:1055–1064
165. Mannan MA, Abir AB, Rahman MR (2015) Antidepressant-like effects of methanolic extract of *Bacopa monniera* in mice. *BMC*

- Complement Altern Med 15:337. <https://doi.org/10.1186/s12906-015-0866-2>
166. Wang Z, Zhang D, Hui S, Zhang Y, Hu S (2013) Effect of *Tribulus terrestris* saponins on behavior and neuroendocrine in chronic mild stress depression rats. *J Tradit Chin Med* 33:228–232. [https://doi.org/10.1016/s0254-6272\(13\)60130-2](https://doi.org/10.1016/s0254-6272(13)60130-2)
 167. Bhattacharya SK, Bhattacharya A, Sairam K, Ghosal S (2000) Anxiolytic-antidepressant activity of *Withania somnifera* glycowithanolides: an experimental study. *Phytomedicine* 7:463–469. [https://doi.org/10.1016/S0944-7113\(00\)80030-6](https://doi.org/10.1016/S0944-7113(00)80030-6)
 168. Müller D, Pfeil T, Von den Driesch V (2003) Treating depression comorbid with anxiety—results of an open, practice-oriented study with St John's wort WS® 5572 and valerian extract in high doses. *Phytomedicine* 10:25–30. <https://doi.org/10.1078/1433-187X-00305>
 169. Ahmadi M, Khalili H, Abbasian L, Ghaeli P (2017) Effect of valerian in preventing neuropsychiatric adverse effects of efavirenz in HIV-positive patients: a pilot randomized, placebo-controlled clinical trial. *Ann Pharmacother* 51:457–464. <https://doi.org/10.1177/1060028017696105>
 170. Amsterdam JD, Shults J, Soeller I, Mao JJ, Rockwell K, Newberg AB (2012) Chamomile (*Matricaria recutita*) may provide antidepressant activity in anxious, depressed humans: an exploratory study. *Altern Ther Health Med* 18:44–49
 171. Chang SM, Chen CH (2016) Effects of an intervention with drinking chamomile tea on sleep quality and depression in sleep disturbed postnatal women: a randomized controlled trial. *J Adv Nurs* 72:306–315. <https://doi.org/10.1111/jan.12836>
 172. Komaki A, Rasouli B, Shahidi S (2015) Anxiolytic effect of *Borago officinalis* (Boraginaceae) extract in male rats. *Avicenna J Neuro Psych Physiol*. <https://doi.org/10.17795/ajnp-27189>
 173. Sayyah M, Sayyah M, Kamalinejad M (2006) A preliminary randomized double blind clinical trial on the efficacy of aqueous extract of *Echium amoenum* in the treatment of mild to moderate major depression. *Prog Neuro-Psychopharmacol Biol Psychiatry* 30:166–169. <https://doi.org/10.1016/j.pnpbp.2005.10.005>
 174. Farahmand M, Khalili D, Ramezani Tehrani F, Amin G, Negarandeh R (2020) Effectiveness of *Echium amoenum* on premenstrual syndrome: a randomized, double-blind, controlled trial. *BMC Complement Med Ther* 20:295. <https://doi.org/10.1186/s12906-020-03084-2>
 175. Farahmand M, Khalili D, Ramezani Tehrani F, Amin G, Negarandeh R (2021) Could anise decrease the intensity of premenstrual syndrome symptoms in comparison to placebo? A double-blind randomized clinical trial. *J Complement Integr Med* 17:1–10. <https://doi.org/10.1515/jcim-2019-0077>
 176. Akhondzadeh S, Kashani L, Fotouhi A, Jarvandi S, Mobaseri M, Moin M, Khani M, Jamshidi AH, Baghalian K, Taghizadeh M (2003) Comparison of *Lavandula angustifolia* Mill. tincture and imipramine in the treatment of mild to moderate depression: a double-blind, randomized trial. *Prog Neuro-Psychopharmacol Biol Psychiatry* 27:123–127. [https://doi.org/10.1016/S0278-5846\(02\)00342-1](https://doi.org/10.1016/S0278-5846(02)00342-1)
 177. Caputo L, Reguilon MD, Miñarro J, De Feo V, Rodriguez-Arias M (2018) *Lavandula angustifolia* essential oil and linalool counteract social aversion induced by social defeat. *Molecules* 23:2694. <https://doi.org/10.3390/molecules23102694>
 178. Nikfarjam M, Rakhshan R, Ghaderi H (2017) Comparison of effect of *Lavandula officinalis* and venlafaxine in treating depression: a double blind clinical trial. *J Clin Diagn Res* 11:KC01–KC04. <https://doi.org/10.7860/JCDR/2017/20657.10233>
 179. Araj-Khodaei M, Noorbala AA, Yarani R, Emadi F, Emaratkar E, Faghihzadeh S, Parsian Z, Aljaniha F, Kamalinejad M, Naseri M (2020) A double-blind, randomized pilot study for comparison of *Melissa officinalis* L. and *Lavandula angustifolia* Mill. and fluoxetine for the treatment of depression. *BMC Complement Med Ther* 20:207. <https://doi.org/10.1186/s12906-020-03003-5>
 180. Liu L, Liu C, Wang Y, Wang P, Li Y, Li B (2015) Herbal medicine for anxiety, depression and insomnia. *Curr Neuropharmacol* 13:481–493. <https://doi.org/10.2174/1570159x1304150831122734>
 181. Sudha K, Deepak G, Sushant K, Vipul P, Nilofer N, Kharade M, Madhukar S (2011) Study of antidepressant like effect of *Coriandrum sativum* and involvement of monoaminergic and gabanergic system. *Int J Res Ayurveda Pharm* 2:267–270. www.ijrap.net
 182. Sahoo S, Brijesh S (2020) Anxiolytic activity of *Coriandrum sativum* seeds aqueous extract on chronic restraint stressed mice and effect on brain neurotransmitters. *J Funct Foods* 68:103884. <https://doi.org/10.1016/j.jff.2020.103884>
 183. (2021) Evaluation of the antidepressant-like effect of the aqueous extract of *Prunus mahaleb* L. seed kernels in mice. *Univ Thi-Qar J Sci*. <https://doi.org/10.32792/utq/utjsci/vol8/1/6>
 184. Fanaei H, Khayat S, Kasaiean A, Javadimehr M (2016) Effect of curcumin on serum brain-derived neurotrophic factor levels in women with premenstrual syndrome: a randomized, double-blind, placebo-controlled trial. *Neuropeptides* 56:25–31. <https://doi.org/10.1016/j.npep.2015.11.003>
 185. Wang Y, Li J, Zhuge L, Su D, Yang M, Tao S, Li J (2014) Comparison between the efficacies of curcumin and puerarin in C57BL/6 mice with steatohepatitis induced by a methionine- and choline-deficient diet. *Exp Ther Med* 7:663–668. <https://doi.org/10.3892/etm.2013.1461>
 186. Iqbal M, Sharma SD, Okazaki Y, Fujisawa M, Okada S (2003) Dietary supplementation of curcumin enhances antioxidant and phase II metabolizing enzymes in ddY male mice: possible role in protection against chemical carcinogenesis and toxicity. *Pharmacol Toxicol* 92:33–38. <https://doi.org/10.1034/j.1600-0773.2003.920106.x>
 187. Khayat S, Fanaei H, Kheirkhah M, Moghadam ZB, Kasaiean A, Javadimehr M (2015) Curcumin attenuates severity of premenstrual syndrome symptoms: a randomized, double-blind, placebo-controlled trial. *Complement Ther Med* 23:318–324. <https://doi.org/10.1016/j.ctim.2015.04.001>
 188. Jafari F, Tabarrai M, Abbassian A, Jafari F, Ayati MH (2021) Effect of garlic (*Allium sativum*) supplementation on premenstrual disorders: a randomized, double-blind, placebo-controlled trial. *Evid Based Complement Altern Med* 2021:1–9. <https://doi.org/10.1155/2021/9965064>
 189. Bhandare SS, Tembhrne SV (2014) Antidepressant effects of dietary supplements Garlic and Black sesame extracts in ovariectomized rats: involving possible estrogenic and antioxidant mechanism. *Int J PharmTech Res* 6:168–173
 190. Rahmani G, Farajdokht F, Mohaddes G, Babri S, Ebrahimi V, Ebrahimi H (2020) Garlic (*Allium sativum*) improves anxiety- and depressive-related behaviors and brain oxidative stress in diabetic rats. *Arch Physiol Biochem* 126:95–100. <https://doi.org/10.1080/13813455.2018.1494746>
 191. Dhingra D, Goyal PK (2008) Evidences for the involvement of monoaminergic and GABAergic systems in antidepressant-like activity of *Tinospora cordifolia* in mice. *Indian J Pharm Sci* 70:761–767. <https://doi.org/10.4103/0250-474X.49118>
 192. Carver CM, Chuang SH, Reddy DS (2016) Zinc selectively blocks neurosteroid-sensitive extrasynaptic δ GABAA receptors in the hippocampus. *J Neurosci* 36:8070–8077. <https://doi.org/10.1523/JNEUROSCI.3393-15.2016>
 193. Heidari H, Amari R, Feizi A, Askari G, Kohan S, Tavasoli P (2019) Vitamin D supplementation for premenstrual syndrome-related inflammation and antioxidant markers in students with

- vitamin D deficient: a randomized clinical trial. *Sci Rep* 9:1–8. <https://doi.org/10.1038/s41598-019-51498-x>
194. Ataollahi M, Ali Akbari SA, Mojab F, Majd HA (2015) The effect of wheat germ extract on premenstrual syndrome symptoms. *Iran J Pharm Res* 14:159–166
 195. Ahmed M, Azmat A (2017) Decreased brain serotonin turnover rate following administration of Sharbat-e-Ahmed Shah produces antidepressant and anxiolytic effect in rats. *Metab Brain Dis* 32:1785–1790. <https://doi.org/10.1007/s11011-017-0065-6>
 196. Thiem B, Kikowska M, Maliński MP, Kruszka D, Napierała M, Florek E (2017) Ecdysteroids: production in plant in vitro cultures. *Phytochem Rev* 16:603–622. <https://doi.org/10.1007/s11011-016-9483-z>
 197. Yasir M, Ali A, Ahmad I, Khan N, Ashraf M (2021) Effect of herbal formulation Sharbat Ahmad Shahi on serum BDNF level in mild to moderate cases of depressive disorder. *J Complement Med Res* 12:265. <https://doi.org/10.5455/jcmr.2021.12.04.39>
 198. Urooj M, Husain GM, Nadeem M, Naikodi MAR, Alam M, Kazmi MH (2020) Antiepileptic and antidepressant activity of Majoon Najah (a traditional Unani Formulation) in experimental animals. *Int J Pharm Investig* 10:396–401. <https://doi.org/10.5530/ijpi.2020.3.70>
 199. Dhingra D, Joshi P, Gupta A, Chhillar R (2012) Possible involvement of monoaminergic neurotransmission in antidepressant-like activity of *Emblica officinalis* fruits in mice. *CNS Neurosci Ther* 18:419–425. <https://doi.org/10.1111/j.1755-5949.2011.00256.x>
 200. Dhingra D, Valecha R (2007) Evaluation of antidepressant-like activity of aqueous and ethanolic extracts of *Terminalia bellirica* Roxb. fruits in mice. *Indian J Exp Biol* 45:610–616
 201. Zakerin S, Hajimehdipoor H, Mortazavi SA, Sabetkasaei M, Choopani R, Fahimi S (2021) A herbal syrup: formulation and antidepressant effect in male rat. *J Rep Pharm Sci* 10:101–109. https://doi.org/10.4103/jrptps.JRPTPS_136_19
 202. Dhingra D, Sharma A (2006) Antidepressant-like activity of *Glycyrrhiza glabra* L. in mouse models of immobility tests. *Prog Neuro-Psychopharmacol Biol Psychiatry* 30:449–454. <https://doi.org/10.1016/j.pnpbp.2005.11.019>
 203. Singh JN, Sunil K, Rana AC (2013) Antidepressant activity of methanolic extract of foeniculum vulgare (fennel) fruits in experimental animal models. *J Appl Pharm Sci* 3:65–70. <https://doi.org/10.7324/JAPS.2013.3912>
 204. Ahmadpoor J, Valipour Chahardahcheric S, Setorki M (2019) The Protective effect of hydroalcoholic extract of the Southern Maidenhair Fern (*Adiantum capillus-veneris*) on the depression and anxiety caused by chronic stress in adult male mice: an experimental randomized study. *Iran Red Crescent Med J*. <https://doi.org/10.5812/ircmj.86750>
 205. Lin SH, Chou ML, Chen WC, Lai YS, Lu KH, Hao CW, Sheen LY (2015) A medicinal herb, *Melissa officinalis* L. ameliorates depressive-like behavior of rats in the forced swimming test via regulating the serotonergic neurotransmitter. *J Ethnopharmacol* 175:266–272. <https://doi.org/10.1016/j.jep.2015.09.018>
 206. Qureshi MA, Husain GM, Urooj M, Khan MA, Husain M, Kazmi MH (2021) Preclinical safety, anxiolytic and antidepressant activity of Sufoof Jawahar Mohra: a Unani formulation. *Adv Integr Med* 8:114–121. <https://doi.org/10.1016/j.aimed.2020.06.003>
 207. Lee G, Bae H (2017) Therapeutic effects of phytochemicals and medicinal herbs on depression. *Biomed Res Int* 2017:1–11. <https://doi.org/10.1155/2017/6596241>
 208. Chan SWY, Harmer CJ, Norbury R, O’Sullivan U, Goodwin GM, Portella MJ (2016) Hippocampal volume in vulnerability and resilience to depression. *J Affect Disord* 189:199–202. <https://doi.org/10.1016/j.jad.2015.09.021>
 209. Wang JQ, Mao L (2019) The ERK pathway: molecular mechanisms and treatment of depression. *Mol Neurobiol* 56:6197–6205. <https://doi.org/10.1007/s12035-019-1524-3>
 210. Koelsch S, Boehlig A, Hohenadel M, Nitsche I, Bauer K, Sack U (2016) The impact of acute stress on hormones and cytokines, and how their recovery is affected by music-evoked positive mood. *Sci Rep* 6:23008. <https://doi.org/10.1038/srep23008>
 211. Reppermund S, Zihl J, Lucae S, Horstmann S, Kloiber S, Holsboer F, Ising M (2007) Persistent cognitive impairment in depression: the role of psychopathology and altered hypothalamic-pituitary-adrenocortical (HPA) system regulation. *Biol Psychiatry* 62:400–406. <https://doi.org/10.1016/j.biopsych.2006.09.027>
 212. Müller MB, Holsboer F (2006) Mice with mutations in the HPA-system as models for symptoms of depression. *Biol Psychiatry* 59:1104–1115. <https://doi.org/10.1016/j.biopsych.2006.02.008>
 213. Tse G, Yan BP, Chan YWF, Tian XY, Huang Y (2016) Reactive oxygen species, endoplasmic reticulum stress and mitochondrial dysfunction: the link with cardiac arrhythmogenesis. *Front Physiol*. <https://doi.org/10.3389/fphys.2016.00313>
 214. Setorki M (2020) Medicinal herbs with anti-depressant effects. *J HerbMed Pharmacol* 9:309–317. <https://doi.org/10.34172/jhp.2020.39>
 215. Fava GA (2002) Long-term treatment with antidepressant drugs: The spectacular achievements of propaganda. *Psychother Psychosom* 71:127–132. <https://doi.org/10.1159/000056279>
 216. Li C, Huang J, Cheng YC, Zhang YW (2020) Traditional Chinese medicine in depression treatment: from molecules to systems. *Front Pharmacol*. <https://doi.org/10.3389/fphar.2020.00586>
 217. Sharma P, Manchanda R, Goswami R, Chawla S (2019) Biodiversity and therapeutic potential of medicinal plants. In: *Environ. Concerns Sustain. Dev. Vol. 2 Biodiversity, Soil Waste Manag.*, pp 27–44. https://doi.org/10.1007/978-981-13-6358-0_2
 218. van Eck NJ, Waltman L (2014) Visualizing bibliometric networks. In: *Meas. Sch. Impact*, pp 285–320. https://doi.org/10.1007/978-3-319-10377-8_13
 219. Bin Heyat MB, Akhtar F, Ansari MA, Khan A, Alkahtani F, Khan H, Lai D (2020) Progress in detection of insomnia sleep disorder: a comprehensive review. *Curr Drug Targets* 22:672–684. <https://doi.org/10.2174/1389450121666201027125828>
 220. Bin-Hayat MB, Akhtar F, Khan MH, Ullah N, Gul I, Khan H, Lai D (2020) Detection, treatment planning, and genetic predisposition of bruxism: a systematic mapping process and network visualization technique. *CNS Neurol Disord Drug Targets* 20:755–775. <https://doi.org/10.2174/1871527319666201110124954>
 221. Sheikh S, Bin Heyat MB, AlShorman O, Masadeh M, Alkhatni F (2021) A review of usability evaluation techniques for augmented reality systems in education. In: *2021 Innov. New Trends Eng. Technol. Sci. Educ. Conf. IETSEC 2021, IEEE*, pp 1–6. <https://doi.org/10.1109/IETSEC51476.2021.9440506>
 222. Akhtar F, Li JP, Bin Heyat MB, Quadri SL, Ahmed SS, Yun X, Haq AU (2019) Potential of blockchain technology in digital currency: a review. In: *2019 16th Int. Comput. Conf. Wavelet Act. Media Technol. Inf. Process. ICCWAMTIP 2019, IEEE, Chengdu*, pp 85–91. <https://doi.org/10.1109/ICCWAMTIP47768.2019.9067546>
 223. Akhtar F, Patel PK, Bin Heyat MB, Yousaf S, Baig AA, Mohona RA, Mutoffar MM, Bhattacharya T, Teelhawod BN, Li JP, Kamal MA, Wu K (2022) Smartphone addiction among students and its harmful effects on mental health, oxidative stress, and neurodegeneration towards future modulation of anti-addiction therapies: a comprehensive survey based on SLR, research questions, and network visualization. *CNS Neurol Disord Drug Targets*. <https://doi.org/10.2174/1871527321666220614121439>
 224. Ortega MA, Alvarez-Mon MA, García-Montero C, Fraile-Martínez O, Guíjarro LG, Lahera G, Monserrat J, Valls P, Mora F, Rodríguez-Jiménez R, Quintero J, Álvarez-Mon M (2022) Gut microbiota metabolites in major depressive disorder—deep

- insights into their pathophysiological role and potential translational applications. *Metabolites* 12:50. <https://doi.org/10.3390/metabo12010050>
225. Claeys EHI, Mantingh T, Morrens M, Yalin N, Stokes PRA (2022) Resting-state fMRI in depressive and (hypo)manic mood states in bipolar disorders: a systematic review. *Prog Neuro-Psychopharmacol Biol Psychiatry* 113:110465. <https://doi.org/10.1016/j.pnpbp.2021.110465>
226. Lv QY, Chen MM, Li Y, Yu Y, Liao H (2022) Brain circuit dysfunction in specific symptoms of depression. *Eur J Neurosci* 55:2393–2403. <https://doi.org/10.1111/ejn.15221>
227. Gunning FM, Oberlin LE, Schier M, Victoria LW (2021) Brain-based mechanisms of late-life depression: implications for novel interventions. *Semin Cell Dev Biol* 116:169–179. <https://doi.org/10.1016/j.semcdb.2021.05.002>
228. Rajkumar RP (2021) Gut hormones as potential therapeutic targets or biomarkers of response in depression: the case of motilin. *Life* 11:892. <https://doi.org/10.3390/life11090892>

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Authors and Affiliations

Md Belal Bin Heyat^{1,2} · Faijan Akhtar³ · Farwa Munir⁴ · Arshiya Sultana⁵ · Abdullah Y. Muaad⁶ · Ijaz Gul^{7,8} · Mohamad Sawan² · Waseem Asghar^{9,10} · Sheikh Muhammad Asher Iqbal^{9,10} · Atif Amin Baig¹¹ · Isabel de la Torre Díez¹² · Kaishun Wu^{1,13}

✉ Md Belal Bin Heyat
belalheyat@gmail.com

✉ Mohamad Sawan
sawan@westlake.edu.cn

Faijan Akhtar
faijanakhtar98@gmail.com

Farwa Munir
farwamunir96@gmail.com

Arshiya Sultana
drarshiya@yahoo.com

Abdullah Y. Muaad
abdullahmuaad9@gmail.com

Ijaz Gul
ejazgul786@hotmail.com; gul.ijaz@sz.tsinghua.edu.cn

Waseem Asghar
wasghar@fau.edu

Sheikh Muhammad Asher Iqbal
siqbal2019@fau.edu

Atif Amin Baig
atif_amin@msu.edu.my; atifameen01@gmail.com

Isabel de la Torre Díez
isator@tel.uva.es

Kaishun Wu
wu@szu.edu.cn; wuks@hkust-gz.edu.cn

¹ IoT Research Center, School of Computer Science and Software Engineering, Shenzhen University, Shenzhen 518060, Guangdong, China

² CenBRAIN Neurotech Center of Excellence, School of Engineering, Westlake University, Hangzhou 310030, Zhejiang, China

³ School of Computer Science and Engineering, University of Electronic Science and Technology of China, Chengdu 611731, Sichuan, China

⁴ Faculty of Medicine, Universiti Sultan Zainal Abidin, 20400 Kuala Terengganu, Malaysia

⁵ Department of Ilmu Qabalat wa Amraze Niswan, National Institute of Unani Medicine, Ministry of AYUSH, Bengaluru, Karnataka, India

⁶ Department of Studies in Computer Science, University of Mysore, Manasagangothri, Mysore 570006, India

⁷ Institute of Biopharmaceutical and Health Engineering, Tsinghua Shenzhen International Graduate School, Tsinghua University, Shenzhen, China

⁸ Center of Precision Medicine and Healthcare, Tsinghua-Berkeley Shenzhen Institute, Shenzhen 518055, Guangdong, China

⁹ Department of Electrical Engineering and Computer Science, Florida Atlantic University, Boca Raton, FL 33431, USA

¹⁰ Department of Biological Sciences, Florida Atlantic University, Boca Raton, FL 33431, USA

¹¹ International Medical School, Management & Science University, Malaysia, Shah Alam, Malaysia

¹² Department of Signal Theory and Communications, University of Valladolid, Valladolid, Spain

¹³ Information Hub, Hong Kong University of Science and Technology, Guangzhou Campus 511453, China